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APPEAL FROM JUDGMENT ENTERED BY THE SECOND JUDICIAL DISTRICT
COURT, DAVIS COUNTY, STATE OF UTAH, THE HONORABLE JON MEMMOTT

Pursuant

to Rule

24 (i) of

the Utah

Rules

of

Appellate

Procedure,1 defendants Ventana Growth Fund ("Ventana") and Thomas
Gephart ("Gephart") hereby adopt and incorporate by reference all
sections of the brief

of Defendant General Biometrics, Inc.'s

("GenBio") Brief filed on or about August 9, 1994, except for
Section

V

dealing

with

GenBio's

counterclaim

for breach

of

fiduciary duty, which does not relate to Ventana and Gephart. For
reasons of judicial economy, Ventana and Gephart have attempted not
to duplicate the same well-reasoned arguments made in GenBio's

L

Addendum E,

Brief. Instead, Ventana and Gephart will provide herein additional
and supplementary arguments to those contained in GenBio's Brief.
JURISDICTION
Plaintiffs took this appeal from the Ruling on Proposed
Findings and Objections entered on September 3, 19932 and the
trial court's judgment entered on September 20, 1993.3

Plaintiffs

filed their notice of appeal on October 15, 1993.4

Defendant

GenBio filed its notice of appeal on its cross appeal on October
28, 1993.5

This Court has jurisdiction of this appeal pursuant to

Utah Code Ann. §78-2a-3(2)(k).6
STATEMENT OF ISSUES AND STANDARD OF REVIEW
Pursuant to Rule

24 (i) of the Utah Rules

of Appellate

Procedure, Ventana and Gephart hereby adopt the "Issues Presented
and Standard of Review" section of GenBio's Brief.
DETERMINATIVE PROVISIONS OF LAW
Counsel

is not

aware

of

any

constitutional

provisions,

statutes, ordinances or rules which are determinative in this case.
STATEMENT OF THE CASE
Pursuant to Rule

24 (i) of the Utah Rules of Appellate

Procedure, Ventana and Gephart hereby adopt the "Statement of the
Case" section of GenBio's Brief.
2

Addendum A.

3

Addendum B.

4

R. 1634-35.

5

R. 1639-40.

6

Addendum D.
2

SUMMARY OF THE ARGUMENT
Pursuant to Rule 24 (i) of the Utah Rules

of Appellate

Procedure, Ventana and Gephart hereby adopt the "Summary of the
Argument" section of GenBio's Brief and also provide the following
summary of arguments contained in this brief.
In supplementation of the points argued in GenBio's Brief,
Ventana

and Gephart

address

four main

issues:

First, that

plaintiffs have failed to marshal the evidence; Second, that the
trial court properly found there was no contract; Third, that any
purported agreement lacked proper authorization; and, fourth, that
the trial court's findings are not fatally inconsistent.
With

the

exception

of

one

citation

to

the transcript,

plaintiffs have failed to marshal the evidence in support of the
findings of the trial court as required by law. Instead, they have
merely argued and cited portions of the evidence which support
their position.

This court should therefore "assume that the

record supports the accuracy of the lower court's conclusions of
law and the application of that law in the case."

Peterson v.

Peterson.7
With respect to contract formation issues, Ventana and Gephart
adopt Section II of GenBio's Brief, "There Is No Contract".

If

this Court affirms the trial court's factual finding that there was
no meeting of the minds on the essential elements of a purchase

7

818 P.2d 1305, 1307-08 (Utah App. 1991).
3

contract in this case, it is unnecessary to consider plaintiffs'
arguments regarding corporate authority and actual authority.
Any purported agreement was not authorized by GenBio for two
reasons.

First, there was no board action which authorized any

purported

agreement.

There

is only one board

of directors

discussion on November 30, 1989 and a later addendum thereto which
deal with the possible sale of the IFA facility.
The minutes

and

the

addendum

reflect

that

Gordy

(then

president of GenBio), and only Gordy, was authorized by the board
to investigate the possible sale of the IFA facility, that he was
to bring any potential offers to the Board for approval, and that
in the event of the Board's approval of such a sale, Mr. Gordy
would be compensated according to the formula set forth in the
addendum.

Nowhere

in

the

language

is

a

contract

of

sale

authorized.
Secondly, Thomas Gephart had neither actual nor apparent
authority to bind the corporation with respect to any purported
agreement.
neither

an

Without board authorization, Thomas Gephart, who was
officer

or

director

lacked

corporate

authority to bind GenBio to any purported agreement.

Apparent

authority is also lacking.

of

GenBio,

Plaintiffs cannot claim that Mr.

Gephart was clothed with any apparent authority on the basis of any
office he held with GenBio, because he held none. Further, as two
of the three directors of GenBio, plaintiffs controlled the votes
of the GenBio Board.
8

Plaintiffs cannot credibly claim that they

R. 1589.
4

were somehow misled by their own acts as the majority of the board
and that defendants are somehow responsible.
Under the recent Utah Supreme Court case of Luddington v.
Bodenvest Ltd.,9 a person claiming apparent authority must have
acted in good faith and in reasonable reliance on the acts which
constitute the grant of apparent authority.

In this case, Condie

and Yarter, as directors of the board had actual knowledge of
Gephart's

lack of authority to bind GenBio to sell the IFA

Facility.

Furthermore, Gephart advised Condie in writing, in the

very letter plaintiffs claim constitutes the contract, that a
contract for the sale of the IFA Facility could only be entered
into after the proposal was reviewed and approved by GenBio's
Board.10

Plaintiffs knew that Gephart had no authority and cannot

reasonably or in good faith assert that Gephart had any apparent
authority.
Finally,
inconsistent.

the

trial

court's

findings

are

not

fatally

The trial court's findings regarding control which

plaintiffs rely upon follow the trial court's heading "Proposed
Findings

of

Fact

Counterclaims.n11

and

Conclusions

of

Law

on

Defendants'

Once the trial court granted the defendants'

Rule 41(b) motion at the end of plaintiffs' case in chief,
plaintiffs' issues regarding apparent authority and control alleged
in the Complaint became moot.

Ventana, Gephart and Townsen did

9

855 P.2d 204 (Utah 1993).

10
n

App. Br. Exh. B; Addendum C.

R . 1592 (emphasis added).
5

have an appropriate degree of influence and involvement with
GenBio. However, there is nothing sinister or unlawful about this,
as the court specifically found12 since during the period of time
that the IFA facility was for sale, Townsen was a director of
GenBio and Ventana was a 24% shareholder and a primary source of
funding for GenBio.

None of the matters argued by plaintiffs

establish that Gephart had authority to bind GenBio to any contract
without board approval.
ARGUMENT
Pursuant to Rule

24 (i) of the Utah Rules of Appellate

Procedure, Ventana and Gephart hereby adopt and incorporate all
sections of Defendant GenBio's Argument, except for the sections
dealing with GenBio's counterclaims.

Ventana and Gephart provide

the following supplement to those arguments.
1^

THE

APPEAL

SHOULD

BE

DISMISSED

BECAUSE

PLAINTIFFS/APPELLANTS HAVE FAILED TO MARSHAL THE
EVIDENCE,
Pursuant to Rule

24 (i) of the Utah Rules

of Appellate

Procedure, Ventana and Gephart hereby adopt Section I. of GenBio's
Brief, "The Appeal Should Be Dismissed For Failure to Marshal The
Evidence" and supplement said section with the following additional
argument.
Utah law holds that an appellant must marshal the evidence in
favor of the findings made by the trial court and then show that

See R. 1593.
6

despite that evidence, the trial court's findings were clearly
erroneous.

In Peterson v. Peterson/13 this Court held,

We set aside findings of fact only when they are
clearly erroneous.
Utah R. Civ. P. 52(a); Davis v.
Davis, 749 P.2d 647, 648 (Utah 1988); Ashton v. Ashton,
733 P.2d 147, 149-50 n.l (Utah 1987).
In making that
determination, we give "due regard" to the "opportunity
of the trial court to judge the credibility of the
witnesses." Utah R. Civ. P. 52(a). A finding is clearly
erroneous when, "although there is evidence to support
it, the reviewing court on the entire evidence is left
with the definite and firm conviction that a mistake has
been committed."
State v. Walker, 743 P.2d 191, 193
(Utah 1987)(quoting United States v. United States Gypsum
Co., 333 U.S. 364, 395 (1948). In challenging findings,
the appellant
must marshal all evidence in favor of the
facts as found by the trial court and then
demonstrate that even viewing the evidence in
a light most favorable to the court below, the
evidence is insufficient to support the
findings of fact. If the appellant fails to
marshal the evidence, the appellate court
assumes that the record supports the accuracy
of the lower court's conclusions of law and
the application of that law in the case.
Saunders v. Sharp, 806 P.2d 198, 199 (Utah
1991) .
The Utah Supreme Court has also stated,
A party seeking to set aside a trial court's findings
carries a heavy burden:
'To mount a successful challenge to the
correctness of a trial court's findings of
fact, an appellant must first marshal all the
evidence supporting the finding and then
demonstrate that the evidence is legally
insufficient to support the findings even in
viewing it in the light most favorable to the
court below.' 14
13

818 P.2d 1305, 1307-08 (Utah App. 1991)

14

Alta Industries
Ltd.
v. Hurst,
846 P.2d 1282, 1286 (Utah
1993) (quoting
Reid v. Mutual of Omaha Ins.,
776 P.2d 896, 899 (Utah
1989); Grayson Roper Ltd.
v. Finlinson,
782 P. 2d 467, 470 (Utah
7

With the exception of only one citation to the transcript,15
plaintiffs have totally failed to marshal the evidence in support
of the findings of the trial court.

Instead, they have merely

argued and cited portions of the evidence which support their
position.

Plaintiffs do not contend that there was any single,

specific act by GenBio's board of directors which informed to them
that Gephart had apparent authority to bind the corporation to sell
the IFA facility to plaintiffs.

Instead, plaintiffs make a

desperate attempt to claim that Gephart had apparent authority of
a very general nature to do almost anything on behalf of GenBio
because he, Duwaine Townsen and Ventana exerted significant control
over GenBio. Plaintiffs' statement of the facts in their brief in
this regard is often inaccurate and not only lacks citations to the
transcript as required by Rule 24(a)(7) of the Utah Rules of
Appellate Procedure, but also in many instances finds no support
whatsoever in the record. This is particularly true for the tirade
of facts regarding the alleged "domination and control" of GenBio
by Ventana, Gephart and Townsen.16

An example of plaintiffs'

approach is their statement that "Ventana also has prevented all
shareholders meetings and has not allowed any information to be
sent to the shareholders, including financial information."17

The

actual finding of the court did not attribute these shortcomings to
1989); In re Estate
15

of Bartell,

776 P.2d 885, 886 (Utah 1998).

App. Br, 7.

16
17

See App. Br. 4-9.

R. 1592 (emphasis added).
8

Ventana.18

In fact it is important to realize that, during most

of the critical time periods, both Condie and Yarter were members
of the GenBio Board. To the extent they are critical of how GenBio
was run, plaintiffs can also blame themselves.

Accordingly, this

court should "assume that the record supports the accuracy of the
lower court's conclusions of law and the application of that law in
the case."

Peterson v. Peterson.19

II,

THERE IS NO CONTRACT,

Pursuant to Rule 24 (i) of the Utah Rules

of Appellate

Procedure, Ventana and Gephart hereby adopts Section II of GenBio's
Brief, "There Is No Contract".

If this Court affirms the trial

court's factual finding that there was no meeting of the minds on
the essential elements of a purchase contract in this case,20 it

18

The actual findings of the court in this regard are as
follows:
3.
The history of the operations of GenBio are
that there was very little consideration of shareholders'
interests in the operation of GenBio and that GenBio was
not run in the manner consistent for providing
shareholder information.
4.
At no time has GenBio ever conducted any
shareholders meetings and there have been no election of
directors by the shareholders in the history of the
corporation.
R. 1592-93.
19

818 P.2d 1305, 1307-08 (Utah App. 1991).

20

The trial court held: "The Court finds that the nature of
the telephone conversations, letters, and subsequent negotiations
between the parties' attorneys established the parties' intent to
enter an agreement to negotiate a final contract, but that final
contract was never signed or agreed upon by the parties." R. 1589.
9

is

unnecessary

to

consider

plaintiffs'

arguments

regarding

corporate authority and actual authority.
Ill,

ANY PURPORTED AGREEMENT WAS NOT AUTHORIZED BY
GENBIO.

Pursuant

to Rule

24 (i) of the Utah

Rules of Appellate

Procedure, Ventana and Gephart hereby adopt Section III of GenBio's
Brief, "Any Purported Agreement Was Not Authorized By GenBio" and
supplement said section with the following additional argument.
A.

There Was No Board Action Which Authorized Any Purported
Agreement.

Paragraph 13 of the Bylaws of GenBio21 confers exclusive
authority to manage the property and business of GenBio on its
Board.22

Paragraph 16(e) of the GenBio Bylaws states that the

Board will designate who is authorized to sign a contract on behalf
of GenBio.23

In the entire record in this case, there is record

of only one board discussion and a later addendum thereto which
deal with the possible sale of the IFA facility.

The minutes of a

special meeting of the GenBio board of directors on November 30,
1989 reflect that:
A discussion was had concerning the possibilities of
selling the Company's MRC division. It was the sense of
the Board that Mr. Gordy [then president of GenBio]
should investigate the possible sale of this division and
should bring any potential offers to the Board for
further discussion and decision.24
2

Addendum F.

22

23

D. Exh. 1.

Id.

24

(emphasis added).

D. Exh. 53; Addendum G; R. 1585.
10

The addendum to these minutes, executed on March 22, 1990, states:
RESOLVED, that in the event of the sale of the Company's
Utah division (MRC), John T. Gordy will be remunerated
for his efforts on the Company's behalf according to the
following schedule:
MRC is sold for less than $500,000; no remuneration.
MRC is sold for $500,000 or greater; Mr. Gordy
receives five (5%) percent of the net sale
amount up to a maximum of Fifty Thousand
($50,000) Dollars. 25
Mr. Gordy testified at trial that he understood the minutes and the
addendum to authorize the actual sale of the IFA facility without
further board approval if the sale was for at least $500,000 in
cash, 26 and the trial court agreed with this interpretation.27
However, the interpretation of the legal effect of documentary
language

such

as

the

board

resolution

and

the

addendum

are

questions of law, and this Court can make its own interpretation
independent

of

the trial

correctness standard.

court's

determination, based

upon a

In Walter E. Heller Western Inc. v. U.S.

Rock Wool Co., Inc., 28 this Court stated, "Questions of contract
interpretation, such as this, are questions of law to which we owe
no deference but review for correctness."29

The clear language

of the minutes and the addendum cited above, even taken together,
do not constitute final authorization of any purported agreement.
25

D. Exh. 53; Addendum H; R. 1585 (emphasis added).

26

June 7 Tr. 32-33, 44

27
28

R. 1585.

787 P.2d 898 (Utah App. 1988).

29

Id.

at 899.
11

Defendants submit that this language simply means that Mr. Gordy,
and only Mr. Gordy, was authorized by the board to investigate the
possible sale of the IFA facility, that he was to bring any
potential offers to the Board for approval, and that in the event
of the Board's approval of such a sale, Mr. Gordy would be
compensated according to the formula set forth in the addendum.
Nowhere in the language is a contract of sale authorized.
Accordingly, the record is devoid of any board authorization
of any purported agreement for the sale of the IFA facility.
B.

Thomas Gephart Had Neither Actual Nor Apparent Authority
To Bind The Corporation With Respect To Any Purported
Agreement.

It follows from the foregoing that Thomas Gephart, had no
actual authority from the board to sell the IFA facility.

The

trial court so found:
The Court finds that the Board of Directors of GenBio
never gave Mr. Thomas Gephart authority to enter into a
contract to sell MRC.30
The question then becomes whether, as plaintiffs assert, Gephart
had apparent authority to bind GenBio to sell the IFA facility to
plaintiffs without board authorization.

It is well settled that

the issue of apparent authority is a factual issue decided by the
trier of fact.31
30

31

The trial court found, "Defendant Gephart did

R. 1586.

Services

Holding Co.,

Inc.

v. Transamerica

Occidental

Life

Ins. Co., 1994 WESTLAW 32139 at 7 (Ariz.App. Div.l February 8,
1994)("the issue of whether [the agent] had apparent authority to
bind [the principal] is a factual question."); Montoya v. Grease
Monkey Holding Corp., 1994 WESTLAW 8663 at 2 (Colo. App. March 10,
1994)("Whether such apparent authority existed is a question of
fact, and the trial court's determination of this issue is binding
12

not have apparent authority to sell MRC or to make a contract to
sell MRC." 32
1.

GenBio Did Not Clothe Gephart With Apparent Authority to
Bind GenBio to a Sale of Its IFA Facility.

Utah has long recognized that it is the acts of the principal
and not the acts of the agent which determine if the agent has
apparent authority.

In City Electric v. Dean Evans Chrysler-

Plymouth,33 the Utah Supreme Court stated,
It is well settled law that the apparent or ostensible
authority of an agent can be inferred only from the acts
and conduct of the principal.
Bank of Salt Lake v.
Corporation of Pres. of Ch., etc., Utah, 534 P.2d 887
(1975). Where corporate liability is sought for acts of
its agent under apparent authority, liability is premised
upon the corporation's knowledge of and acquiescence in
the conduct of its agent which has led third parties to
rely upon the agent's actions. Kiniski v. Archway Motel,
Inc., Wash.App., 21 Wash.App. 555, 586 P.2d 502 (1978);
Restatement, Agency 2d Sec. 43. Nor is the authority of
the agent "apparent" merely because it looks so to the
person with whom he deals. Id. It is the principal who
must cause third parties to believe that the agent is
clothed with apparent authority.-3^
This principle is similarly recognized in other jurisdictions.

In

Podolan v. Idaho Legal Aid Services, Inc., 35 the Idaho Court of
Appeals stated,

if
supported
by
sufficient
competent
evidence.")(citing
Heatherridge
Management Co. v. Benson,
192 Colo. 190, 558 P.2d 435
(1976)).
32

R. 1590.

33

672 P.2d 89 (Utah 1983).

3

Bank

*Id. at 90 (emphasis added).
See also Zions First
Nat'l
v. Clark Clinic
Corp.,
762 P.2d 1090, 1095 (Utah 1988).
35

854 P.2d 280, 287 (Idaho App. 1993).
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Apparent authority exists where a principal voluntarily
places an agent in a position where "a person of ordinary
prudence conversant with the business usages and the
nature of the particular business, is justified in
believing that the agent is acting pursuant to existing
authority."

Apparent authority cannot be created by the acts and
statements of the agent alone. One must use reasonable
diligence to ascertain the agent's authority. Reasonable
diligence encompasses a duty to inquire with the
principal about the agent's authority. If no inquiry is
made, the third party is chargeable with knowing what
kind of authority the agent actually had, if any, "and
the fault cannot be thrown on the principal who never
authorized the act or contract."Jb
The Arizona Court of Appeals has similarly held,
As to apparent authority, "the principal must make some
manifestation to the third party which could reasonably
be relied upon to indicate that the agent had the alleged
authority. ,,JV
Thomas Gephart was neither an officer nor a director of GenBio
during December, 1990 and January 1991 when the discussions took
place with Robert Condie about the possible sale of the IFA
facility. Gephart had not been a director of GenBio since March of
1989.38

Condie knew this because he himself was a member of the

GenBio board of directors

from December of

resignation of December 31, 1990.40

36

Id.

until his

James Yarter was a director

(emphasis added).

31

Hartford
v. Industrial
1206 (Ariz. App. 1994) .

Commission

38

June 8 Tr. 26.

39

June 2 Tr. 239.

40

198739

D. Exh. 36.
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of Arizona,

870 P.2d 1202,

of GenBio from September 1989 until his resignation on December 13,
1990.41

He also became Chairman of the Board of GenBio in March

1990 and became acting president of GenBio in June of 1990.42
Therefore, plaintiffs cannot claim that Mr. Gephart was clothed
with any apparent authority on the basis of any office he held with
GenBio.
In City Electric v. Dean Evans Chrysler-Plymouth,43 the Utah
Supreme Court held,
Moreover, it has been held that apparent authority vanishes
when the third party has actual knowledge of the real scope of
the agent's authority.44
As directors of GenBio, plaintiffs knew there was no formal board
approval for Gephart to bind the corporation. They knew he was not
an officer or director of the corporation. And finally, they knew
that board approval was reguired for significant actions.45
Furthermore, under the case authority cited above, plaintiffs
cannot rely on any of Gephart's acts or statements to support their
argument that Gephart had apparent authority to consummate a deal.
Therefore, even if Gephart told Condie, as Condie testified, that
Gephart "was now in charge of [GenBio]" and that if Condie "had any
further interest in pursuing the purchase of MRC, that [Gephart

41

June 2 Tr. 68.

*2Id.
43

672 P.2d at 90,

44

Citing
Bank of Oregon v. Highway
Or.App. 223, 598 P.2d 318 (1979)).
45

Products,

See Findings of Fact, 5 10H, R. 1587-88.
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Or.App., 41

was] the one

[Condie] should contact,"45 it does not matter

because an agent cannot clothe himself with apparent authority.47
Plaintiffs' argument that Gephart had apparent authority to
negotiate and ultimately sell the MRC division is like a dog
chasing its tail.

As shown above, apparent authority can only be

manifested to a third party from the acts of the principal. As two
of the three directors of GenBio, plaintiffs controlled the votes
of the GenBio Board.

Yarter was the Chairman of the Board.

Plaintiffs therefore constituted two-thirds of GenBio's Board, the
"principal", which they now contend misled them.

Incredibly,

plaintiffs allege that they were somehow misled by their own acts
as the majority of the board and that defendants are somehow
responsible.

It is anomalous indeed, that plaintiffs contend

Gephart had apparent authority because their claim amounts to the
fact that they were both on the "giving" and the "receiving" end of
the apparent authority issue.
The trial court was not persuaded by plaintiffs' arguments
about domination and control because it specifically reviewed each
action claimed by plaintiffs in their case in chief to support
their claim of apparent authority and found that "the actions
alleged by Plaintiffs do not establish unity of interest or
authority of control giving Mr. Gephart apparent authority.48
46

June 2 Tr. 100; App. Br. 22.

47

City Electric,

48

672 P.2d at 90,

A.
The contract that Mr. Yarter claimed
to have had with GenBio was in fact a contract
with Ventana that did not establish control
16

Based upon these findings the trial court correctly found that:
"Defendant Gephart did not have apparent authority to sell MRC or

over GenBio.
B.
The claimed transfer of $200,000 from
GenBio to Darox to cancel debts was in fact paid to
Ventana not to Darox in order to retire notes and
liabilities. The transfer was to an improper transfer by
GenBio but, rather, was a repayment that was proper.
C.
The Practitioners Agreement [with the
Swedes] was not evidence of improper control by Ventana
because the January 14, 1990 Board Minutes reflect Board
approval of the Practitioners Agreement.
D.
Mr. Gephart's visit to GenBio did not
establish control of GenBio by Ventana.
E.
The fact that Mr. Monson asked for a
confirmation from Mr. Gephart as to the terms of his
separation as reflected in the March 17, 1988 Board
Minutes did not establish inappropriate control because
the minutes also reflect that Mr. Gephart was given
authority from the Board to deal with the issue.
F.
Ventana's investment in GenBio and the
loans to GenBio did not result in inappropriate control
over GenBio. There was no evidence presented other than
that money given to GenBio from Ventana were represented
by proper notes and warrants. These transactions did not
reflect payments for control of GenBio but, rather, were
investments in GenBio.
G.
The move of GenBio's headguarters from
Salt Lake City to San Diego did not evidence improper
influence.
The overall business plan of the merger
between Datagene and MRC and the creation of GenBio
always contemplated that GenBio's headguarters would be
moved to San Diego.
H.
The Board Meeting of April 30, 1990 where
Mr. Gephart sat in for Mr. Townsen did not evidence
improper influence. While the minutes show that Mr.
Gephart sat in as a representative of Ventana, Mr.
Gephart did not vote on any of the issues and did not
take a role as a director in voting on those issues.
R. 1587-88.
17

to make a contract to sell MRC."4^

The trial court specifically

found that Gephart did not have the apparent authority alleged by
plaintiff's in their complaint.
2.

Plaintiffs Did Not Act In Good Faith and Did Not
Reasonably
Rely
on
the
Alleged
Appearance
of
Authority.

The

Utah

Supreme

Court

recently

decided

Luddington

v.

Bodenvest Ltd./50 where the plaintiff successfully argued at trial
that

a principal was

liable under the doctrine

of apparent

authority. On appeal, the Utah Supreme Court held that a plaintiff
asserting that apparent authority exists must show that he "knew of
the facts and, acting in good faith, had reason to believe, and did
actually believe, that the agent possessed such authority."51

In

essence, this means that a person claiming apparent authority must
have acted in good faith and in reasonable reliance on the acts
which constitute the grant of apparent authority by the principal.
In this case, Condie and Yarter had actual knowledge of
Gephart's

lack of authority to bind GenBio to sell the IFA

Facility.

In 1989, the Board authorized its former president,

Gordy, to investigate the possibility of selling MRC and to "bring
any potential offers to the Board for further discussion and
decision."

49

52

Condie and Yarter were both members of the Board at

R. 1590.

50

855 P.2d 204 (Utah 1993).

sl

Id.

at 209.

52

See Minutes of Nov. 30, Defendants' Exhibit 53.
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the time this direction was given.

Thus, plaintiffs were aware

that no one had authority to enter into a contract to sell the IFA
Facility without approval of the Board. Gephart advised Condie in
writing, in the very letter plaintiffs claim constitutes the
contract, that a contract for the sale of the IFA Facility could
only be entered into after the proposal was reviewed and approved
by GenBio's Board.54

This constitutes an admission by Gephart

that he did not have actual or apparent authority, and plaintiffs
had notice of his lack of board authority to bind the corporation.
It is one thing to negotiate a sale; it is quite another thing to
have the authority to bind a corporation to the sale. As shown in
Section V of GenBio's Brief, which details GenBio's Counterclaim
for breach of fiduciary duty, plaintiffs did not act in good faith
throughout their dealings with GenBio.

Plaintiffs knew that

Gephart had no authority and cannot reasonably or in good faith
assert that Gephart had any apparent authority.
IV.

THE

TRIAL

COURT'S

FINDINGS

ARE

NOT

FATALLY

INCONSISTENT.
Pursuant to Rule

24 (i) of the Utah Rules of Appellate

Procedure, Ventana and Gephart hereby adopt Section IV of GenBio's
Brief, "The Trial Court's Findings Are Not Fatally Inconsistent"
and supplement said section with the following additional argument.

53

ia.

54

App. Br. Exh. B.
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It is important to view the Findings of Fact and Conclusions
of Law in the way the trial court did. Note that the trial court's
findings regarding control which plaintiffs rely upon follow the
trial court's heading "Proposed Findings of Fact and Conclusions of
Law on Defendants' Counterclaims."55 Once the trial court granted
the defendants' Rule 41(b) motion at the end of plaintiffs' case in
chief, plaintiffs'

issues

regarding

apparent

authority56

and

control57 alleged in the Complaint became moot, and defendants did
not put on evidence they otherwise might have done.

The only

remaining issues after the trial court granted defendants' Rule
41(b)

motion

were

whether

Gephart

had

made

any

negligent

misrepresentations58 and whether plaintiffs were liable to GenBio
for breach of fiduciary duty on GenBio's counterclaim. The control
issue is not implicated by these remaining claims.
It appears that the trial court, in fashioning its Findings of
Fact and Conclusions of Law, largely adopted the proposed findings
and conclusions submitted by the prevailing parties on the claims
of

the

Complaint

respectively.
findings

and

on

the

claims

of

the

Counterclaim,

Unfortunately, this appears to have resulted in

regarding

the

issue

of

control

of

GenBio

on

the

Counterclaim which have no relevance to the allegations of the

55

R. 1592 (emphasis added).

56

Complaint 5 42, R. 9.

57

Complaint 51 56-59, R. 12.

58

Plaintiffs have abandoned this issue on appeal.
20

Counterclaim.59

The findings regarding control of GenBio in the

"Counterclaim" section of the Findings of Fact and Conclusions of
Law

are

not

relevant

or

material

to

the

determination

of

defendants' breach of fiduciary duty claim against plaintiffs
asserted in the counterclaim.

Plaintiffs now attempt to use these

superfluous findings to support their claims of apparent authority
in their complaint, but these findings were only adopted by the
trial court with respect to the counterclaim, and should be
disregarded when analyzing the plaintiffs' claims.60 Furthermore,
as argued in GenBio's Brief, plaintiffs are estopped from claiming
these findings are inconsistent because they represented to the
trial court that they are not inconsistent with the trial court's
findings on plaintiffs' claims.
Ventana, Gephart and Townsen did have an appropriate degree of
influence and involvement with GenBio.
unlawful

about

this,

as

However, there is nothing

sinister

or

the

found.61

Indeed, during the period of time that the IFA facility

was for sale, Townsen was a director of GenBio.

court

specifically

Ventana was a 24%

shareholder and a primary source of funding for GenBio.

The

claimed inconsistency in the findings is easily harmonized by

by

See Proposed Findings of Fact and Conclusions of Law on
Defendants' Counterclaims 55 2-10, 27-38, R. 1592-97.
60

Plaintiffs assured the court below that their proposed
findings regarding control did not relate to the apparent authority
issue, but instead related to the breach of fiduciary duty
counterclaim. R. 1530-42. They are therefore estopped to assert
these findings in connection with their apparent authority claim.
61

See R. 1593.
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recognizing that it would be natural for a shareholder and lender
to exert influence over the corporation; however, plaintiffs failed
to establish any improper control by Gephart or Ventana which would
justify reversing the trial court's judgment,
CONCLUSION
At its core, this case boils down to the irrefutable fact that
there was never a meeting of the minds between the parties on the
essential terms of a contract.

The appeal can and should be

decided on this issue alone, if not on the procedural failure of
plaintiffs to properly marshal the evidence in favor of the trial
court's findings. Should this Court decide to reach the remaining
issues in the case, it is quite clear that any purported agreement
never was given proper corporate authorization and, in particular,
Gephart lacked actual or apparent authority as he himself advised
plaintiffs in his January 10, 1991 letter.

Finally, although it

was unnecessary and irrelevant for the trial court to adopt any
findings regarding the issue of "control" with respect to GenBio's
counterclaim, such findings are not inconsistent, as plaintiffs
themselves argued below.

For these reasons, the judgment of the

trial court should be AFFIRMED.
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Addendum F

Tab A

IN THE SECOND DISTRICT COURT OF DAVIS COUNTY
STATE OF UTAH
t .
'••

C & Y CORPORATION, ROBERT A.
CONDIE, AND JAMES YARTER,
Plaintiffs,

J

3

- i ,j '33

,n:

RULING ON PROPOSED FINDINGS
AND OBJECTIONS

v.
GENERAL BIOMETRICS, VENTANA
GROWTH FUND, AND THOMAS
GEPHART,
Defendants.

Case No. 910751194

The Court has reviewed the following information in this case: The Court's ruling of
the trial, Findings of Fact and Conclusions of Law Regarding Plaintiffs Misrepresentation
Claim, Plaintiffs Objections to Defendants' Proposed Findings of Fact and Conclusions of
Law Regarding Plaintiffs' Misrepresentation Claim, Defendant Gephart's Reply to Plaintiffs'
Objections to Defendant's Proposed Findings of Fact and Conclusions of Law Regarding
Plaintiffs' Misrepresentation Claim, Plaintiffs Memorandum and Reply to Defendant Gephart's
Response to Plaintiffs' Objections to Defendants' Proposed Findings of Fact and Conclusions
of Law Regarding Plaintiffs' Misrepresentation Claim, General Biometrics, Inc.'s Response to
Plaintiffs' Objection to Proposed Findings of Fact and Conclusions of Law, Plaintiffs' Reply to
General Biometrics Inc.'s Response to Plaintiffs Objection to Proposed Findings of Fact and
Conclusions of Law, Findings of Fact and Conclusions of Law, Plaintiffs' Objections to
Defendants' Proposed Findings of Fact and Conclusions of Law, Proposed Findings of Fact
and Conclusions of Law on Defendants' Counterclaims, Defendants' Objections to Plaintiffs'
Proposed Findings of Fact and Conclusions of Law, Plaintiffs' Response to Defendants'

Objection to Plaintiffs Proposed Findings of Fact and Conclusions of Law, the evidence from
trial, and the published depositions. The Court makes the following Findings of Fact and
Conclusions of Law.
I.
FINDINGS OF FACT AND CONCLUSIONS OF LAW
(Submitted by Mary Anne Q. Wood, Anthony B. Quinn and Paul M. Durham)
FINDINGS OF FACT
1.

Defendant General Biometrics, Inc. ("GenBio"), is a publicly-held corporation

Defendant Ventana Growth Fund, a California limited partnership ("Ventana"), owns less than
twenty four percent (24%) of GenBio stock.
2.

At GenBio's Board of Directors Meeting ("Board Meeting") held November 30,

1989, the Board authorized Mr. John T. Gordy to investigate the possible sale of MRC. The
Court found the Board of Directors authorized Mr. Gordy to sell MRC Division for $500,000
or more in a cash sale. For any sale less than $500,000 cash, Mr. Gordy was instructed to
bring those offers to the Board for further discussion and decision.
3.

An addendum to the November 30, 1989 Board Minutes provided that:

RESOLVED, that, in the event of the sale of the Company's Utah division (MRC),
John T. Gordy will be remunerated for his efforts on the Company's behalf according
to the following schedule:
MRC is sold for less than $500,000; no remuneration.
MRC is sold for $500,000 or greater; Mr. Gordy receives five
(5%) percent of the net sale up to a maximum of Fifty Thousand
($50,000) Dollars.

Defendants' Exhibit No. 53.
4.

The Court found based upon testimony that GenBio and Mr. Gordy entered

into an incentive contract for the sale of MRC. Plaintiff Yarter testified that he was the
GenBio director who negotiated and drew up the incentive contract and that the approval
given by GenBio was for a cash sale of MRC for $500,000. This contract was not introduced
into evidence because it was not found during the discovery process.
5.

Mr. Gordy testified that it was his understanding of the agreement that if the

sale of MRC were for even a penny less than $500,000, the sale would have to go back to the
Board for approval.
6.

The Court finds the two letters of January 1991 were not cash sales because the

January 7th letter from Mr. Condie to Mr. Gephart indicated a purchase price of $500,000
with $350,000 in cash to be paid upon closing. The $350,000 was later crossed out and a
figure of $400,000 was inserted. The remainder of the proposed purchase price would be
paid by Plaintiffs paying $75,000 90 days after closing with an additional $25,000 to be paid
120 days after closing.
7.

The Court finds there was no contract between GenBio and Plaintiffs because

the sale of MRC proposed in telephone conversations in December of 1990 and in January of
1991, and in the letters of January of 1991 were outside the scope of authority given by the
Board, (i.e. this was not a cash sale in excess of $500,000) and therefore, further Board
approval, which was required, was not obtained.
8.

The Court finds that the Board of Directors of GenBio never gave Mr. Thomas

Gephart authority to enter into a contract to sell MRC.
9.

At all material times, Venlana Growth Fund II, L.P., was not a majority

shareholder of GenBio. All Ventana entities combined own less than twenty four percent
(24%) of GenBio's stock with just over eleven percent (11% ) in preferred stock held by
Ventana Growth Fund I, LP., and just over eleven (11%) in common stock held by Ventana
Growth Fund II, L.P. In addition, Ventana loaned money to GenBio for which it received
warrants that were convertible into stock. The warrants were not converted into stock and
therefore, the Court did not find this material in terms of ownership.
10.

The following actions alleged by Plaintiffs do not establish unity of interest or

authority of control giving Mr. Gephart apparent authority.
A.

The contract that Mr. Yarter claimed to have had with GenBio was in

fact a contract with Ventana that did not establish control over GenBio.
B.

The claimed transfer of $200,000 from GenBio to Darox to cancel debts

was in fact paid to Ventana not to Darox in order to retire notes and liabilities. The transfer
was not an improper transfer by GenBio but, rather, was a repayment that was proper.
C.

The Practitioners Agreement was not evidence of improper control by

Ventana because the January 14, 1990 Board Minutes reflect Board approval of the
Practitioners Agreement.
D.

Mr. Gephart's visit to GenBio did not establish control of GenBio by

E.

The fact that Mr. Monson asked for a confirmation from Mr. Gephart as

Ventana.

to the terms of his separation as reflected in the March 17, 1988 Board Minutes did not
establish inappropriate control because the minutes also reflect that Mr. Gephart was given
authority from the Board to deal with the issue.
F.

Ventana's investment in GenBio and the loans to GenBio did not result

in inappropriate control over GenBio. There was no evidence presented other than that
money given to GenBio from Ventana were represented by proper notes and warrants These
transactions did not reflect payments for control of GenBio but, rather, were investments in
GenBio.
G.

The move of GenBio's headquarters from Salt Lake City to San Diego

did not evidence improper influence The overall business plan of the merger between
Datagene and MRC and the creation of GenBio always contemplated that GenBio's
headquarters would be moved to San Diego
H.

The Board Meeting of April 30, 1990 where Mr Gephart sat in for Mr

Townsen did not evidence improper influence

While the minutes show that Mr Gephart sat

in as a representative of Ventana, Mr Gephart did not vote on any of the issues and did not
take a role as a director in voting on those issues.
11.

Mr. Condie testified that Mr Gephart called him on the 2nd, 3rd or 4th of

January and offered to sell MRC for $500,000 at $400,000 down with the balance in 60 or 90
days.
12.

Mr. Condiefs January 7th letter was not an acceptance of the oral offer of Mr

Gephart's because it varied the terms as to the time of payment and the amount thereof.
Therefore, there was no meeting of the minds as to the specific terms of the agreement as
recited between the telephone conversations and the letter of January 7, 1991.
13.

Mr. Gephart's January 10th letter was not an acceptance of the offer contained

in the January 7th letter because the terms vary on several essential points. First, Gephart's
letter discussed the sale of assets and liabilities while Condie's letter discussed only the sale
of assets. The Court received conflicting testimony as to whether the term sale of assets

includes sale of Board assets and liabilities. Gephart's letter also established a different sale
price and also established a condition that the plan for the purchase and sale of MRC would
be taken to the Board within the next week to receive formal approval.
14.

The Court finds that the nature of the telephone conversations, letters, and

subsequent negotiations between the parties' attorneys established the parties' intent to enter an
agreement to negotiate a final contract, but that final contract was never signed or agreed
upon by the parties.
15.

The conduct of the parties and other evidence considered by the Court

reinforced the Court's finding that a final agreement was not made. The three drafts of the
agreement and Mr. Condie's testimony in relation to those drafts show that there were several
essential terms on which the parties did not agree. The parties disagreed as to the noncompetition clause, the allocation of employee related liabilities, consulting arrangements
between MRC and GenBio, and how accounts receivable and leased equipment would be
handled. During negotiations, plaintiffs never communicated to defendants that they would
compromise on these terms.
CONCLUSIONS OF LAW
1.

Pursuant to Rule 41(b) of the Utah Rules of Civil Procedure defendants are

entitled to have plaintiffs1 claims against them dismissed with prejudice because after
completing the presentation of their evidence plaintiffs have shown no right to relief based
upon the facts and the law.
2.

41(b) is appropriately invoked when the trial judge finds that the claimant has

either failed to make out a prima facie case or where the trial judge is not persuaded by the
evidence presented by the claimant.

3.

When considering a 41(b) motion, the Court is allowed a certain latitude to

weigh the evidence and draw inferences therefrom.
4.

Because the evidence presented by plaintiffs is insufficient to make out a prima

facie case the Court is required to enter a decision for defendants on their motion for
dismissal under Rule 41(b) of the Utah Rules of Civil Procedure.
5.

Defendant Gephart did not have actual authority to sell MRC or to make a

contract to sell MRC.
6.

Defendant Gephart did not have apparent authority to sell MRC or to make a

contract to sell MRC.
7.

The circumstances of this case show that the conversations in December of

1990 and January of 1991, and the letters exchanged in January of 1991 were preliminary
negotiations to enter a contract and were not a final agreement or contract.
8.

It is not necessary that the contract itself contain all the particulars of the

agreement. The crucial question is whether the parties agreed on the essential terms of the
contract.
9.

Extrinsic evidence considered by the Court to delineate the intent of the parties

and the enforceability of the contract established that the minds of these parties did not meet
on essential terms.
10.

The correspondence and draft agreements and additional testimony establish

that the parties did not mutually agree on the contract essential terms.
11.

While plaintiffs placed a great deal of reliance on Rand Whitney Packaging

Corp. v. The Robertson Group. Inc . 651 F. Supp. 520 (D. Mass. 1986), there are substantial
differences between some key elements of the Rand Whitney case and this case. Particularly,

the parties in Rand Whitney engaged in extensive negotiations in which they dealt with many
of the specific details for making the agreement prior to making the contract. In this case,
plaintiffs did not present evidence that such details had been agreed upon prior to the time the
contract was alleged to have been made. The package of information developed by GenBio
to give to potential purchasers of MRC was not evidence of agreed upon terms because the
package was not part of any specific negotiations between the parties.
12.

Of major importance to this court is the difference in conduct of the seller in

Rand Whitney and the seller in this case. In Rand Whitney, after the seller had made the
offer it told prospective purchasers the company had been sold and the company otherwise
conducted itself as if the sale had actually taken place. In this case, GenBio's conduct
indicated that MRC was still for sale. GenBio continued to negotiate the sale of MRC with
parties other than plaintiff. In late December of 1990 and in January of 1991, Mr. Dorsett
had conversations with GenBio and Mr. Townsen regarding Dorsett's potential purchase of
MRC. The conversations and all activities taking place between Mr. Dorsett and GenBio
indicated that MRC was still for sale. And while Mr. Dorsett was told that an offer was on
the table, Mr. Dorsett and GenBio continued to negotiate the purchase and sale of MRC.
13.

Another difference between Rand Whitney and the present case relates to the

board approval given in these cases. In Rand Whitney a specific proposal to sell to a specific
company was taken to the board of directors. The board approved the specific sale for a
specific dollar amount to a specific company. It was not a general approval to sell to anyone
within the terms. The Court in Rand Whitney went into great detail in establishing why it
believed the board actually approved the specific sale at issue and that the minds of the
parties had met. However, there is a significant factual distinction between the Rand Whitney

case and the case presented by plaintiffs in this case. The only agreement reached in the
present matter was an agreement to negotiate a final purchase and sale contract. With respect
to these negotiations, this Court makes the assumption that they were made in good faith
14.

Since no contract to sell MRC was ever formed between the parties, the issues

of specific performance, lost profits and reverse piercing of the corporate veil are moot and
will not be decided by the Court.
15.

The Court reserves and does not decide the issue of adequacy of tender as the

defendants failed to include that issue in the pre-trial order and the Court doesn't feel that
issue is properly before the Court
II.
PROPOSED FINDINGS OF FACT AND CONCLUSIONS OF LAW ON
DEFENDANTS' COUNTERCLAIMS
FINDINGS OF FACT
1.

GenBio is a Delaware Corporation with its principal place of business located

in California. They also have a separate facility located in Bountiful, Utah.
2.

Defendant Ventana Growth Fund ("Ventana") is a California Limited

partnership with its principal place of business located in California and is a major
shareholder of GenBio. The managing partners of Ventana are Defendant Thomas Gephart
and Duwaine Townsen.
3.

The history of the operations of GenBio are that there was very little

consideration of shareholders' interests in the operation of GenBio and that GenBio was not
run in the manner consistent for providing shareholder information.
4.

At no time has GenBio ever conducted any shareholders meetings and there

have been no election of directors by the shareholders in the history of the corporation.
5.

Mr. Gephart and Mr. Townsen exercised a great deal of control over the

GenBio Board of Directors and the operation of GenBio, however, this influence did not rise
to the level of being a violation of law.
6.

With the exception of Mr. Condie, all of the GenBio directors were either

employees of Ventana, consultants who had a relationship with Ventana, shareholders with
another portfolio company of Ventana, or GenBio employees. The appointment of all
directors were at the direction of Mr. Gephart or Mr. Townsen. Mr. Gephart or Mr. Townsen
controlled who subsequent directors would be and controlled the appointment of the directors
in this case.
7.

Many of the decisions to hire key personnel, rather than being made by the

GenBio Board of Directors independently, were made either by Mr Gephart or Mr. Townsen
Mr. Gordy, who was hired as president, was instructed to talk to Mr. Gephart and Mr.
Townsen rather than deal with Mr. Monson, who was the CEO of GenBio. At this time, Mr
Gephart was neither a director nor an officer of GenBio
8.

When there was a dispute between the officers, it was Mr. Gephart who was

involved in the resolution of the dispute, not the Board of Directors. This included a dispute
between Mr. Yarter and Mr. Monson, which resulted in the decision to terminate Mr.
Monson. This decision was made by Mr. Gephart and not the Board of Directors.
9.

In considering the evidence adduced on whether Mr. Gephart or the Board

made this decision, and the testimony of Mr. Gephart on what has happened in GenBio in
general, the Court has serious reservations on the credibility of Mr. Gephart's testimony. Mr
Gephart had substantial influence in the operation of GenBio, but has little, if no, recollection

on what has occurred.
10.

Mr. (jephart and Mr. Townsen had a great deal of control in the decision when

to recall loans and the time of payments, rather than the GenBio Board of Directors, or
independent officers, being able to control when money was sent. The decisions to recall
loans and the timing of payments were made in the best interests of Ventana, rather than the
best interests of GenBio.
11.

Robert A. Condie was a member of the GenBio Board of Directors from July

1987 until December 31, 1990.
12.

Mr. Yarter served on the GenBio Board of Directors from November 1989 until

November 30, 1990.
13.

Although Mr Condie was a director when he first contacted Mr. Townsen to

make an offer to purchase the MRC Division, Mr. Condie specifically resigned from the
Board so that he could enter subsequent negotiations for the purchase and sale of MRC
Division and consummate an agreement.
14.

Mr. Yarter resigned from the Board prior to the time when any offers for the

purchase and sale of the MRC Division were made.
15.

Even after resigning from the Board of Directors in November 1990, Mr.

Yarter introduced Dr. Preston Dorsett to GenBio for the purpose of Dr. Dorsett negotiating for
the purchase and sale of the MRC Division.
16.

When Mr. Condie rented his condominium in Park City, Utah to GenBio, there

was a benefit to the corporation rather than an abuse of corporate authority. Three people
were occupying the condominium for approximately $125 a week.
17.

The receipt by Mr. Condie of health insurance provided by GenBio was not an

abuse of discretion and did not constitute an improper benefit

It appeared to be a custom

and practice of this corporation to provide such benefits
18

Mr Condie as a director regularly requested that shareholder meetings be held

as required by the By-Laws
19

Other benefits also were provided to Board members, the board minutes of

November 30, 1989 show that the Board took action to provide Ventana a $2,000 per month
consulting fee for prior service for approximately eight to fifteen months based on the fact
that Mr townsen had put in excess time prior to that
20

The information Mr Condie or Mr Yarter obtained in making their decision to

pursue the purchase of the MRC Division was not of a confidential nature and was the same
information which had been sent to other potential purchasers

The information which Mr

Condie of Mr Yarter received also was the same information sent to Dr Dorsett
21

Prior to the time Mr Condie and Mr Yarter had any interest in purchasing the

MRC Division, the GenBio Board of Directors authorized its sale for $500,000 cash in
November 1989
22

Information relating to the MRC Division, including financial information, was

segregated for the express purpose of providing this information to prospective purchasers
23

During the November 30, 1989 Board meeting, the Board of Directors gave

Mr Gordy approval to sell MRC for $500,000 or more and that Mr Gordy would receive a
five percent commission for the sale of the MRC Division

Mr Gephart and Mr Townsen

also gave their approval to sell the MRC Division prior to the November 30, 1989 meeting
24

Mr Gordy's testimony indicated that he regularly marketed the sale of MRC

for a six to eight month period

25.

Mr. Gordy met regularly with Mr. Gephart and Mr. Townsen and reported to

them on the sale of the MRC Division.
26.

GenBio's reasons for desiring to sell MRC were to raise capital for the

development of the ImmunoDot technology, which was the future of GenBio. The IFA
technology, of which the MRC Division consisted, was an antiquated technology and in a
harvest mode.
27.

Subsequent to this Board meeting, GenBio entered into listing agreements with

Geary Berlew, Waldon & Associates and Ventura, which was a business associate of Mr.
Gephart. The listing agreement with Ventura was entered at the request of Mr. Gephart.
28.

Although Mr. Gephart did not have actual authority to sell MRC he had

substantial knowledge of GenBio and the MRC Division and was involved in negotiations to
sell the MRC Division, even though he was not a member of the GenBio Board.
29.

Other efforts to sell the MRC Division include negotiations with Dr. Dorsett.

Dr. Dorsett initially contacted Mr. Townsen, but Mr. townsen referred him to Mr. Gephart.
30.

Dr. Dorsett indicated to Mr. Gephart that his company was prepared to make

an offer for the purchase and sale of the MRC Division in the range of $500,000 to $600,000
and that they would like to send one of their employees to MRC to perform due diligence.
31.

Mr. Gephart stated to Dr. Dorsett at that time that an in-house offer in the

same range was on the table and that Dr. Dorsett needed to act quickly if he was interested in
purchasing MRC.
32.

Dr. Dorsett did not believe he could meet the restrictions and time table set by

Mr. Gephart and withdrew his offer.
33.

The Board of Director's approval for the sale of MRC has never been rescinded

by any subsequent Board or Board meeting.
34.

The MRC Division clearly was for sale beginning in November of 1989 Prior

approval of that sale also had been obtained from both Mr. Gephart and Mr. Townsen prior to
it going to the Board of Directors for approval.
35.

The business opportunity and information regarding the potential of MRC had

been available to GenBio and its officers, and particularly in this case, had been available to
Mr. Gephart and Mr. Townsen. Mr. Gephart and Mr. Townsen had available to them the
same knowledge and information that was available to Mr. Condie and Mr. Yarter.
36.

Every six months, Mr. Gephart and Mr. Townsen performed a full evaluation

of each of the business opportunities of their portfolio companies, including GenBio.
37.

The same information also was fully disclosed to Mr. Gephart and Mr.

Townsen on at least a bimonthly basis.
38.

Mr. Gephart, although not a board member, was present at the April 30, 1990

Board meeting wherein Mr. Gordy gave a report to the Board of the possible sale of MRC.
Mr. Gephart was present at this meeting in Mr. townsen's absence as a representative of
Ventana. Mr. Gephart requested that he be sent copies of all sales literature and material
which was sent to potential purchasers. Mr. Gordy also reported at this meeting that
information regarding MRC had been segregated for potential buyers.
CONCLUSIONS OF LAW
1.

The Court adopted the following legal standards in reaching conclusions of

law.
A.

Pursuant to the fiduciary duty of loyalty, the corporate opportunity

doctrine forbids a corporate director from acquiring for his own benefit an opportunity that

would have been valuable and germane to the corporation's business, unless that opportunity
is first presented to the corporation and it is declined by a disinterested board of directors, or,
where that is not possible, by action of the stockholders.
B.

The doctrine of corporate opportunity forbids a corporate director from

acquiring for his own benefit an opportunity that would have been valuable and germane to
the corporation's business, unless that opportunity is first offered to the corporation and
declined.
2.

Counterclaim plaintiff has not shown that Mr. Condie or Mr. Yarter breached

any fiduciary duties when they decided to investigate the possible purchase of the MRC
Division.
3.

Counterclaim plaintiff has not shown that Mr. Condie or Mr. Yarter gained

access to, or improperly used, confidential information of GenBio to establish a competing
corporation and urging GenBio to sell the MRC Division in such a manner that would have
been detrimental to GenBio and its stockholders.
4.

Counterclaim plaintiff has not shown that Mr. Condie or Mr. Yarter diverted

or attempted to divert to themselves opportunities which in fairness and equity belonged to
GenBio.
5.

The Court finds it doesn't need to raise the question to pierce the corporate veil

because of the Court's previous findings.
III.
FINDINGS OF FACT AND CONCLUSIONS OF LAW
REGARDING PLAINTIFFS MISREPRESENTATION CLAIM
FINDINGS OF FACT

1.

The Court finds from the testimony of Plaintiff Robert Condie ("Condie ") that

on December 22, 1990. defendant Thomas Gephart ("Gephart") called Condie at his home
and told Condie that Gephart was in charge of Ventana (which the Court believes Condie
really meant to say "GenBio"), that Duwaine Townsen ("Townsen") was "burned out", that
Gephart was going to reorganize the board of directors of defendant General Biometrics, Inc
("GenBio"); and if Condie had any further interest in pursing the purchase of MRC that
Gephart was the one Condie should contact
2.

During that conversation, Gephart told Condie that at a multiple of two or three

times earnings, GenBio may be worth one million to two million dollars, that Gephart knew
that Condie knew that Gephart was the manning running Ventana (GenBio) and MRC, and
that the board would — the new board would be a perfunctory thing, and that if Condie had
an interest that they should get together
3.

The Court also finds the foregoing conversation consistent with Condie's

version of the conversation in his deposition testimony at page 78 of his deposition, namely
that Gephart informed Condie that Townsen was no longer the chairman of the board, that
Gephart had taken over as chairman; that Townsen was burned out, and that Gephart was
going to appoint some new directors that had some pizazz and some high visibility, that any
dealings that Condie would want to do as far as the purchase of MRC should be done through
Gephart; and that as the chairman of the board and the general partner of Ventana that
Gephart was in a position to consummate a deal and asked Condie for an offer; that the board
as it was and as it would be was a perfunctory thing, that Condie knew that Gephart
controlled and would make the decisions for General Biometrics.
4.

On January 10, 1991, Gephart sent Condie a letter in which he sated: "I will

plan to take this proposal to the GenBio Board of Directors within the next week, to receive
formal approval."
5.

The statements made by Gephart to Condie on December 22, 1990 and in his

letter of January 10, 1991, were made in good faith at the time they were made and Gephart
at that time intended to follow through on those statements.
6.

During subsequent negotiations which occurred during the months of January

through March 1991, GenBio and plaintiffs were never able to agree on essential terms of an
agreement and board approval by GenBio for the proposed sale of MRC was never given.
7.

Gephart expected plaintiffs to rely on his representations of authority to sell the

MRC Division and the plaintiffs did in fact reasonably rely on those representations. Based
on the representations of Gephart, the plaintiffs hired legal counsel, and incurred costs
thereby, to draft a purchase and sale agreement, and that the legal counsel hired by plaintiffs
did communicate with counsel for GenBio and other corporate officers. Based on the
representations of Gephart, plaintiffs also incurred costs in obtaining financing to purchase the
MRC Division. The Court finds that these representations and discussions were in the nature
of negotiations to reach a final contract rather than making a final agreement to sell.
CONCLUSIONS OF LAW
1.

The Court finds the standard the standard applicable to the plaintiffs' cause of

action for negligent misrepresentation is stated in the Utah Supreme Court case of Jardine v.
Brunswick Corp.. 423 P.2d 659 (Utah 1967), as follows:
Where one having a pecuniary interest in a transaction, is in a superior position
to know material facts, and carelessly or negligently makes a false representation
concerning them, expecting the other party to rely and act thereon, and the other party

reasonably does so and suffers loss in that transaction, the representor can be held
responsible if the other elements of fraud are also present.
Id at 662 (citing Pace v. Parrish. 122 Utah 247 P 2d 273 (Utah 1952).
2.

The statements made by Gephart, and particularly that "the board was a

perfunctory thing or perfunctory purpose" and his implicit promise to obtain board approval
do not constitute negligent misrepresentations under the definition set down by the case of
Cerritos Trucking Co. v Utah Venture No 1. 645 P 2d 608 (Utah 1982). In Cerntos, the
Utah Supreme Court stated that there is no negligent misrepresentation "when the promisor's
expression of intention to perform is made in good faith even though he may have been
negligent in assessing and weighing the various factors which influenced him in formulating
that intention." Id. at 612.
3.

Gephart's statement that he would get board approval and that it would be

perfunctory was consistent with his January 10 letter that he would present Condie's offer to
the board and get board approval The Court finds that the promise or statement made in this
case falls within the facts of the Cerntos case. In that case, the Utah Supreme Court stated
that where a promise is made in good faith, there is no fraud if "the promisor subsequently
changes his mind and fails or refuses to perform " Id. at 612.
4.

The Court finds in this case that there was a good faith promise made by

Gephart to obtain board approval, however, because of the subsequent negotiations in which
the parties could not agree on essential terms as evidenced by the testimony of Mr. EHson and
Mr. Flodin, there never was a meeting of the minds on essential terms of a contract.
Therefore, there was no agreement. Based on that finding and on the March 6, 1991 GenBio
board meeting, at which time there was not approval, the Court finds that there was a change

of mind by Gephart whereby he failed or refused to perform.
5.

Plaintiffs claim for negligent misrepresentation against Gephart is hereby

denied based upon plaintiffs' failure to establish any misrepresentation as to any past or
present material fact or a present promise which Gephart did not intend to perform at the t
it was made.
Dated this

3 ^

day of S e p ^ . .

, 1993.

BY THE COURT

_J frv^- ttYttWJr

DISTRICT COURT JUDGE

Certificate of Mailing:
I certify that I mailed a true and correct copy of the foregoing Ruling on the
J5l c{

day of September, 1993, postage prepaid, to the following:

ROBERT S. CAMPBELL
PAUL T. MOXLEY
ROBERT E MANSFIELD
One Utah Center, Thirteenth Floor
201 South Main Street
Salt Lake City, Utah 84111
PAUL M DURHAM
1200 Beneficial Life Tower
36 South State Street
Salt Lake City, Utah 84111
MARY ANNE Q WOOD
ANTHONY B QUINN
500 Eagle Gate Tower
60 East South Temple
Salt Lake City, Utah 84111

/ /

-y nu
Deputy Clerk/

/

fiat,

TabB

n\ r V"

'

riLETr IN CLARK'S Or?iC!T
fi.V/;:, • /••-• • T> •

WOOD SPENDLOVE & QUINN, L.C,
Mary Anne Q. Wood #3 5 39
Anthony B. Quinn #2 67 4
5 00 Eagle Gate Tower
60 East South Temple
Salt Lake City, Utah 8 4111
(801) 366-6060

SEP

r 4

20 II on Ml *93

CL*ihK. d!u* w/V..CC'JKr

«_**£
DEPUTY CLIZK*

Attorneys for Defendant
General Biometrics, Inc.
IN THE SECOND JUDICIAL DISTRICT COURT IN AND FOR DAVIS COUNTY
STATE OF UTAH

CSY CORP., a Utah corporation,
ROBERT A. CONDIE, an individual,
and JAMES YARTER, an individual,
Plaintiffs,

JUDGKENT
;

V,

GENERAL BIOMETRICS, INC., a
Delaware corporation; VENTANA
GROWTH FUND, a California
limited partnership, and THOMAS
GEPHART, an individual,
Defendants.

i

Civil No. 910751194
Judge Jon ML Memmott

]

This action came on for trial before the above-entitled
court with Honorable Jon M. Memmott, District Judge presiding.
The issues having been duly tried and the court having rendered
its findings of fact and conclusions of law,
IT IS ORDERED AND ADJUDGED:
That the plaintiff take nothing on its complaint, that
the complaint be dismissed on the merits;
That defendant take nothing on its counterclaim/ that
the counterclaim be dismissed on the merits; and

/

That each party shall bear its own costs and attorneys'
fees.
DATED this 1 p*1 day of September, 1993.

BY THE COURT:

Honorable Jon M. Mejwnott
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Via Facsimile: (801) 363-1588

D

January 10, 1991

Mr. Robert Condi*
BRIGHTON HOSPrrALITY GROUP
50 South 400 East
Suite 116
Salt Lake City, UT 84111
Dear Bob:
Pursuant to your January 7 correspondence and to our telephone conversation yesterday
afternoon, I would like to provide a written acknowledgement of the agreement regarding
the sale of assets and liahflrriri of MRC from GenBio for $500,000. As I mentioned, we
generally agree with your proposal.
Please note, however, that the capital amounts in Sections (B), (C) and (D) of your proposal
only total 5450,000. In mis regard, I would like to modify section (B) to be increased to
$400,000 - instead of 5350,000 - so that the total will add up to the entire S500,000. .1
will plan to take this proposal to the GenBio Board of Directors within the next week, to
receive formal approval.
I will look forward to speaking with you shortly.
Sincerely yours,
VENTANA

Thomas O. Gephart
Managing Partner
TOGAck
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JUDICIAL CODE
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a successor is appointed and qualified. The presiding
judge of the Court of Appeals shall receive as additional compensation $1,000 per annum or fraction
thereof for the period served.
(2) The Court of Appeals shall sit and render judgment in panels of three judges. Assignment to panels
shall be by random rotation of all judges of the Court
of Appeals. The Court of Appeals by rule shall provide for the selection of a chair for each panel. The
Court of Appeals may not sit en banc.
(3) The judges of the Court of Appeals shall elect a
presiding judge from among the members of the court
by majority vote of all judges. The term of office of the
presiding judge is two years and until a successor is
elected. A presiding judge of the Court of Appeals
may serve in that office no more than two successive
terms. The Court of Appeals may by rule provide for
an acting presiding judge to serve in the absence or
incapacity of the presiding judge.
(4) The presiding judge may be removed from the
office of presiding judge by majority vote of all judges
of the Court of Appeals. In addition to the duties of a
judge of the Court of Appeals, the presiding judge
shall:
(a) administer the rotation and scheduling of
panels;
(b) act as liaison with the Supreme Court;
(c) call and preside over the meetings of the
Court of Appeals; and
(d) carry out duties prescribed by the Supreme
Court and the Judicial Council.
(5) Filing fees for the Court of Appeals are the
same as for the Supreme Court.
1988
78-2a-3. C o u r t of A p p e a l s j u r i s d i c t i o n .
(1) The Court of Appeals has jurisdiction to issue
all extraordinary writs and to issue all writs and process necessary:
(a) to carry into effect its judgments, orders,
and decrees; or
(b) in aid of its jurisdiction.
(2) The Court of Appeals has appellate jurisdiction,
including jurisdiction of interlocutory appeals, over:
(a> the final orders and decrees resulting from
formal adjudicative proceedings of state agencies
or appeals from the district court review of informal adjudicative proceedings of the agencies, except the Public Service Commission, State Tax
Commission, Board of State Lands, Board of Oil,
Gas, and Mining, and the state engineer;
(b) appeals from the district court review of:
(i) adjudicative proceedings of agencies of
political subdivisions of the state or other local agencies; and
(ii) a challenge to agency action under
Section 63-46a-12.1;
(c) appeals from the juvenile courts;
(d) appeals from the circuit courts, except
those from the small claims department of a circuit court;
(e) interlocutory appeals from any court of
record in criminal cases, except those involving a
charge of a first degree or capital felony;
(f) appeals from a court of record in criminal
cases, except those involving a conviction of a
first degree or capital felony;
(g) appeals from orders on petitions for extraordinary writs sought by persons who are incarcerated or serving any other criminal sentence, except petitions constituting a challenge to
a conviction of or the sentence for a first degree
or capital felony;

(h) appeals from the orders on petitio
traordinary writs challenging the decisinS f ° r e**
Board of Pardons except in cases involvi° nS ° fl ^
degree or capital felony;
^ a fir^
(i) appeals from district court involve
tic relations cases, including, but not i,
^
divorce, annulment, property division c h ^ t°tody, support, visitation, adoption, and nat Cu*"
y
(j) appeals from the Utah Military C 0u
ar
(k) cases transferred to the Court of A ^
ppe
from the Supreme Court.
alj
(3) The Court of Appeals upon its own moti
n n
and by the vote of four judges of the court mav ° ^
to the Supreme Court for original appellate
T^
and determination any matter over which the n"1**
of Appeals has original appellate jurisdiction ° Un
(4) The Court of Appeals shall comply with th
quirements of Title 63, Chapter 46b, in its revi * *"
w
agency adjudicative proceedings.
°^
78-2a-4. R e v i e w of a c t i o n s by Supreme Co
Review of the judgments, orders, and decrees of tk
Court of Appeals shall be by petition for writ of «»*.*
°fcerti.
orari to the Supreme Court.
78«2a-5. Location of Court of Appeals.
The Court of Appeals has its principal location
Salt Lake City. The Court of Appeals may perform
any of its functions in any location within the state
i*

CHAPTER 3
DISTRICT C O U R T S
Section
78-3-1 to 78-3-2. Repealed.
78-3-3.
Term of judges — Vacancy.
78-3-4.
Jurisdiction — Transfer of cases to circuit court — Appeals — Jurisdiction
when circuit and district court
merged.
78-3-5.
Repealed.
78-3-6.
Terms — Minimum of once quarterly
78-3-7 to 78-3-11. Repealed.
78-3-11.5.
State District Court Administrative
System.
78-3-12.
Repealed.
78-3-12.5.
Costs of system.
78-3-13.
Repealed.
78-3-13.4.
Counties joining court system — Procedure — Facilities — Salaries.
78-3-13.5, 78-3-14. Repealed.
78-3-14.5.
Allocation of district court fees and
fines.
78-3-15 to 78-3-17. Repealed.
78-3-17.5.
Application of savings accruing to
counties.
78-3-18.
Judicial Administration Act — Short
title.
78-3-19.
Purpose of act.
78-3-20.
Definitions.
78-3-21.
Judicial Council — Creation — Members — Terms and election — Responsibilities — Reports.
78-3-21.5.
Data bases for judicial boards.
78-3-22.
Presiding officer - - Compensation Duties.
78-3-23.
Administrator of the courts — Appointment — Qualifications — Salary.
78-3-24.
Court administrator — Powers, duties, and responsibilities.
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same standards as the review of findings of fact in other appeals.
(Added effective October 1, 1992.)
NOTES TO DECISIONS
Allegation of facts required.
Because defendant did not allege any facts in
support of his ineffective assistance claim, the
appellate court would not remand the case for
an evidentiary hearing. It would be improper

to remand a claim under this rule for a fishmp
expedition State v. Garrett. 849 P.2d 573
(Utah Ct. AppJ, cert, denied, 860 P. 943 (Utah
1993).

Rule 24. Briefs.
(a) Brief of the appellant. The brief of the appellant shall contain under
appropriate headings and in the order indicated:
( D A complete list of all parties to the proceeding in the court or
agency whose judgment or order is sought to be reviewed, except where
the caption of the case on appeal contains the names of all such parties.
The list should be set out on a separate page which appears immediately
inside the cover.
(2) A table of contents, with page references.
(3) A table of authorities with cases alphabetically arranged and with
parallel citations, rules, statutes and other authorities cited, with references to the pages of the brief where they are cited.
(4) A brief statement showing the jurisdiction of the appellate court.
(5) A statement of the issues presented for review and the standard of
appellate review with supporting authority for each issue.
(6) Constitutional provisions, statutes, ordinances, rules, and regulations whose interpretation is determinative shall be set out verbatim with
the appropriate citation. If the pertinent part of the provision is lengthy,
the citation alone will suffice, and in that event, the provision shall be set
forth as provided in paragraph (f) of this rule.
(7) A statement of the case. The statement shall first indicate briefly
the nature of the case, the course of proceedings, and its disposition in the
court below. A statement of the facts relevant to the issues presented for
review shall follow. All statements of fact and references to the proceedings below shall be supported by citations to the record in accordance with
paragraph (e) of this rule.
(8) Summary of arguments. The summary of arguments, suitably
paragraphed, shall be a succinct condensation of the arguments actually
made in the body of the brief. It shall not be a mere repetition of the
heading under which the argument is arranged.
(9) An argument. The argument shall contain the contentions and reasons of the appellant with respect to the issues presented, with citations
to the authorities, statutes, and parts of the record relied on.
(10) A short conclusion stating the precise relief sought.
(b) Brief of the appellee. The brief of the appellee shall conform to the
requirements of paragraph (a) of this rule, except that a statement of the
issues or of the case need not be made unless the appellee is dissatisfied with
the statement of the appellant.
(c) Reply brief. The appellant may file a brief in reply to the brief of the
appellee, and if the appellee has cross-appealed, the appellee may file a brief
in reply to the response of the appellant to the issues presented by the crossappeal. Reply briefs shall be limited to answering any new matter set forth in
the opposing brief. The content of the reply brief shall conform to the requirements of paragraph (a)(2), (3), (6), (9), and (10) of this rule. No further briefs
may be filed except with leave of the appellate court.
(d) References in briefs to parties. Counsel will be expected in their
briefs and oral arguments to keep to a minimum references to parties by such
designations as "appellant" and "appellee." It promotes clarity to use the
designations used in the lower court or in the agency proceedings, or the
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Rule 24

actual names of parties, or descriptive terms such as "the employee," "the
injured person," "the taxpayer," etc.
(e) References in briefs to the record. References shall be made to the
pages of the original record as paginated pursuant to Rule 1Kb), to pages of
the reporter's transcript, or to pages of any statement of the evidence or
proceedings or agreed statement prepared pursuant to Rule 11(0 or 11(g).
References to exhibits shall include exhibit numbers. If reference is made to
evidence the admissibility of which is in controversy, reference shall be made
to the pages of the transcript at which the evidence was identified, offered,
and received or rejected.
(0 Reproduction of statutes, rules, regulations, documents, etc. If determination of the issues presented requires the study of statutes, rules, regulations, etc., or relevant parts thereof, to the extent not set forth under subparagraph (a)(6) of this rule, they shall be reproduced in the brief or in an
addendum at the end, or they may be supplied to the court in pamphlet form.
Copies of those parts of the record on appeal that are of central importance to
the determination of the appeal (e.g., the challenged instructions, findings of
fact and conclusions of law, memorandum decision, the contract or document
subject to construction, etc.) shall also be included in the addendum.
(g) Length of briefs. Except by permission of the court, principal briefs
shall not exceed 50 pages, and reply briefs shall not exceed 25 pages, exclusive
of pages containing the table of contents, tables of citations and any addendum containing statutes, rules, regulations, or portions of the record as required by paragraph (f) of this rule.
(h) Briefs in c a s e s involving cross-appeals. If a cross-appeal is filed, the
party first filing a notice of appeal shall be deemed the appellant for the
purposes of this rule and Rule 26, unless the parties otherwise agree or the
court otherwise orders. The brief of the appellee shall contain the issues and
arguments involved in the cross-appeal as well as the answer to the brief of
the appellant.
(i) Briefs in c a s e s involving multiple appellants or appellees. In cases
involving more t h a n one appellant or appellee, including cases consolidated
for purposes of the appeal, any number of either may join in a single brief, and
any appellant or appellee may adopt by reference any part of the brief of
another. Parties may similarly join in reply briefs.
(j) Citation of supplemental authorities. When pertinent and significant
authorities come to the attention of a party after that party's brief has been
filed, or after oral argument but before decision, a party may promptly advise
the clerk of the appellate court, by letter setting forth the citations. An original letter and nine copies shall be filed in the Supreme Court. An original
letter and seven copies shall be filed in the Court of Appeals. There shall be a
reference either to the page of the brief or to a point argued orally to which the
citations pertain, but the letter shall without argument state the reasons for
the supplemental citations. Any response shall be made within 7 days of filing
and shall be similarly limited.
(k) Requirements and sanctions. All briefs under this rule must be concise, presented with accuracy, logically arranged with proper headings and
free from burdensome, irrelevant, immaterial or scandalous matters. Briefs
which are not in compliance may be disregarded or stricken, on motion or sua
sponte by the court, and the court may assess attorney fees against the offending lawyer.
(1) Brief covers. The covers of all briefs shall be of heavy cover stock and
shall comply with Rule 27.
(Amended effective October 1, 1992.)
Advisory Committee Note. — The brief
must now contain for each issue raised on appeal, a statement of the applicable standard of
review and citation of supporting authority.

Amendment Notes. — The 1992 amendment, effective October 1, 1992, added the
third sentence in Subdivision (c) and made styiistic changes in Subdivisions (a)(5) and (7).
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GENERAL BIOMETRICS, INC.
BYLAWS
OFFICES
1.

The corporation shall have ? registered office and

maintain a registered agent i n tl le Sta tie
2.

Uaware.

The corporation may also have offices at such

other places as the board of directors may from time to time
designate or the business of the corporat :i en ma\ req aire.

SEAL
3.

The corporate seal shall have

inscribed thereon

the name of the corporation, the year of its organization and the
words "Corporate Seal, Delaware"•

•'> I'OCKHOLDER ' JJ MEET 1II ;
4.

All meetings of the stockholders shall be held at

the office of the corporation, or at such place as may be fixed
by the board of dir

cified

... . of the

meeting.
The annual meeting of the stockholders, after the
year 1978, shall be held or the last
within

HI u,i,

iLiaieui. in each year, if

ic;. JL legal holiday, and

if a legal holiday, then on the next sec ilar day following, at
2:00 p.

they shall elect by a plurality vnfp

l.

to serve for one year and tiiiLii their*
successors are elected or chosen and qualified.

of,

6.

The holders of thirty-five (35%) percent of the

stock issued and outstanding entitled to vote, present in person
or represented by proxy, shall be requisite and shall constitute
a quorum at all meetings of the stockholders for the transaction
of business, except as otherwise provided by law, by the
certificate of incorporation or by these bylaws.

If, however,

such majority shall nor be present or represented, the
stockholders present in person, or by proxy shall have power to
adjourn the meeting from time to time, without notice other than
announcement at the meeting, until the requisite amount of stock
shall be present.

At such adjourned meering at which the

requisite amount of stock shall be represented, any business may
be transacted which might have been transacted at the meeting as
originally notified.
7.

At each meeting of the stockholders, every

stockholder having the right to vote shall be entitled to vote in
person, or by proxy, appointed by an instrument in writing
subscribed by such stockholder or by his duly authorized attorney
and delivered to the inspectors at the meeting, and he shall have
one vote for each share of stock having ' roting power, registered
in his name on the books of the corporation.
Except where the transfer books of the corporation
shall have been closed or a date shall have been fixed as a
record date for the determination of its stockholders entitled to
vote, as hereinafter provided, no share of stock shall be voted
on at any election for directors which hr.s been transferred on
GBI/061490/EEB
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the books of the corporation within twenty (20) days next
preceding such election.
8.

Written notice of the annual meeting shall be

mailed to each stockholder entitled to vote thereat, at such
address as appears on the stock ledger of the corporation, at
least ten (10) days prior to the meeting
9.

A complete list of the stockholders entitled to

vote at the ensuing election, arranged in alphabetical order,
with the residence of each, and the number of shares held bv
each, shall be prepared and filed in the office where the
election is to be held, at least ten (10> days before every
election and shall, at all times, during the usual hours for
business and during the whole time of sa. d election, be open to
the examination of any stockholder.
10.
purpost

Special meetings of the sto c kh o ] d e r s , f :::) r a i i} -

purposes, other than those reiulated by statute, may

be called by the chief executive officer, and shall be called by
the chief executive officer or secretary at the request i i I
writing of a ma j on: i t; y

i! !. "ie board of directors, or at the

request in writing by stockholders owning a majority in amount of
the entire capital stock of the corporation issued and
''ii,v

outstanding and entitled
purpose

luesi iiiuiij .bi.ate i.he

purposes of the proposed meeting,
11.

Business transacted at all special meetings shall

be confined to the objects in the call and mntiters efeniune
there ui. ,
GBI, 0>
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12.

Written notice of a special meeting of

stockholders, stating the time and place and object thereof shall
be mailed, postage prepaid, at least ten (10) days before such
meeting, to each stockholder entitled to vote thereat, at such
address as appears on the books of the corporation.

DIRECTORS
13.

The property and business of the corporation shall

be managed by its board of directors which shall be at least
three (3) but not more than nine (9) in rumber, as may from year
to year be established by the board prior- to the annual meeting,
and who need not be stockholders.

They .shall be elected by the

stockholders at the annual meeting of stockholders of the
corporation, and each director shall be elected to serve for the
term of one year, and until his successors shall be elected and
qualified.

Until further action is taken by the board the number

of directors is 3, and any vacancies created by an increase in
the number of directors may be filled by the directors for the
term remaining before the next annual meeting of the
stockholders.
The directors shall elect a chairman of the board at
each annual meeting.
14.

The directors may hold their meetings and have one

or more offices and keep the books of the corporation, except the
original or duplicate stock ledger, outside of Delaware, at such
places as they may from time to time determine.
GBI/061490/EEB
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15.

In addition to the powers and authority by these

bylaws expressly conferred upon it, the board may exercise all
such

the corporation and do all such lawful acts and

things as are not by statute or by the certificate of
incorporation or by these bylaws directed or required to
exercised or done by the stockholders.
16.

Without prejudice to the general powers conferred

by the last preceding clause, and the other powers conferred by
the statute, bv Mv* certificate of incorporation and by these
bylaws, it is hereby expressly declared that the board of
directors shall have the following powers, that is to say:
(a)

From time to time to make and change the
rules and regulations not inconsistent with
these bylaws, for the management of the
corporation's business and affairs.

(b)

To purchase or otherwise acquire for the
corporation any property, rights, or
privileges which the corporation is
authorized to acquire, at such price or
consideration and generally on such terms
conditions as they thing fit.

(c)

At their discretion to pay for any property
or rights acquired by the corporation, either
wholly or partly in money, stock, bonds
debentures or other securities of the
corporation.

(d)

i create, make and issue mortgages, bonds,
deeds of trust, trust agreements ad
negotiable or transferable instruments and
securities, secured by mortgage or otherwise
and to do every other act and thing necessary
to effectuate the same.

(e)

To determine who shall be authorized on the
corporation's behalf to sign bills, notes,
receipts, acceptances, endorsements, checks,
releases, contracts ..:nd documents.

5

(f)

To delegate any of the powers of the board in
the course of the current business of the
corporation to any standing or special
committee or to any officer or agent or to
appoint any persons to be the agents of the
corporation, with such powers (including the
power to sub-delegate) and upon such terms as
they think fit.
MEETINGS OF THE BOARD

17.

The newly elected board may meet at such place and

time as shall be fixed by the vote of the stockholders at the
annual meeting for the purpose of organization and otherwise, and
no notice of such meeting shall be necessary of the newly elected
directors in order to legally constitute the meeting:

PROVIDED a

majority of the whole board shall be present; or such place and
time may be fixed by the consent in writing of all the directors.
18.

Regular meetings of the board may be held without

notice at the said time and place as shall from time to time be
determined by the chairman or a majority of the other members of
the board.
19.

At all meetings of the board a majority of the

directors shall be necessary and sufficient to constitute a
quorum for the transaction of business, and the act of a majority
of the directors present at any meeting at which there is a
quorum, shall be the act of the board of directors, except as may
be otherwise specifically provided by statute or by the
certificate of incorporation or by these bylaws.
20.

Special meetings of the board may be called by the

chief executive officer on two (2) days' notice to each director,
GBI/061490/EEB
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either personally or my mail or by telegram; special meetings
shall be called by the chief executive officer or secretary in
like manner and on like notice

'.he written request of two (2)

directors.
OFFICERS
21.

The officers of the corporation shall be the chief

executive officer, a president or chief operating officer, one or
more vice presidents, a secretary and a treasurer.
of the aforesaid offices, except those or
and secreta
22.

Any two (2)

hi"! ^.etuLive officer

be filled by the same person.
The board of directors, at its first meeting after

each annual meeting of the stockholders, sha

chief

executive officer, from their own number, and the board shall
also annually choose a president, one or more vice presidents, a
secretary and a treasurer who need not bo. members
23.

The board may appoint such other officers and

agents as it shall deem necessary, who shall have such authority
and shall perform such duties as from tine to time shall be
prescribed by the board.
24

. ries of all officers and agents of the

corporation shall be fixed by the board of directors.
25.

The officers of the corporation sha] 3 1: i o] d office

until their successors .ur chosen and qualified in their stead.
officer elected or appointed by the board of directors may be
removed at any time by the affirmative vr.te of a
whole board of directors.
GBI/061490/EEB
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EXECUTIVE COMMITTEE
26.

There may be an executive committee of two or more

directors appointed by the board, who may meet at stated times,
or on notice to all by any of their own number.

During the

intervals between the meetings of the board, they shall advise
with and aid the officers of the corporation in all matters
concerning its interests and the management of its business, and
generally perform such duties and exercise such powers as may be
directed or delegated by the board of directors from time to
time.

The board may delegate to such committee authority to

exercise all the powers of the board, excepting power to amend
the bylaws. Vacancies in the membership of the committee shall
be filled by the board of directors at a regular meeting or at a
special meeting called for that purpose.
27.

The executive committee snail keep regular minutes

of its proceedings and report the same to the board when
required.

THE CHIEF EXECUTIVE OFFICER
28.

The chief executive officer shall direct and

supervise the president and all other officers; he shall develop
and implement the corporation's policies and procedures; he shall
preside at all meetings of the stockholders and directors; he
shall see that all orders and resolutions of the board are
carried into effect, subject however, to the right of the
directors to delegate any specific powers, except such as may be
GBI/061490/EEB
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by statute exclusively conferred on the chief executive officer,
to any other officer or officers of the corporation.
29.

He shall execute bonds, mortgages

other

contracts requir ii :i j a seal, under the seal of the corporation; he
shall keep in safe custody the seal of the corporation, and, when
authorized by the board, affix the seal to any instrument
requiring the

samp, and the seal when so affixed shall be

attested by the signature of the secretary or the treasurer.

He

or the president shall sign certificates of stock.
30.

He shall be i i .:>:-officio member of all standing

committees.

THE PREST DKMT .
The president shall be the chief operating officer
of the corporation; he shall direct the day-to-day business
operations of the corporation c i i ::i si rpex: i :i se the employees of the
corporation; in the absence or disability of the chief executive
officer, he shall perform the duties and exercise the powers of
the chief executive officer; he shall

i'«i

'Ti !\u:ates ol stock.

VICE PRESIDENT
32.

The vice president shall, in the

disability of the president, perform the duties and exercise the
powers of the president, and shall perform such other duties as
shall from time to time be imposed upon him by the board.
event of there being more than MUM
GBI/061490/EEB
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In the

n H" pies uient, each vice

president shall have such duties as shall be assigned to him by
the board of directors.

THE SECRETARY
33.

The secretary shall attend all sessions of the

board and all meetings of the stockholders and act as clerk
thereof, and record all votes and the minutes of all proceedings
in a book to be kept for that purpose; and shall perform like
duties for the standing committees when required.

He shall give,

or cause to be given, notice of all meetings of the stockholders
and of the board of directors, and shall perform such other
duties as may be prescribed by the board of directors or chief
executive officer under whose supervision he shall be.
sign certificates of stock.

He may

He shall be sworn to the faithful

charge of his duty.

THE TREASURER
34.

The treasurer shall have the custody of the

corporate funds and securities and shall keep full and accurate
accounts of receipts and disbursements in books belonging to the
corporation and shall deposit all money and other valuable
effects in the name of and to the credit of the corporation, in
such depositories as may be designated by the board of directors.
35.

He shall disburse the funds of the corporation as

may be ordered by the board, taking proper vouchers for such
disbursements and shall render to the chief executive officer and
GBI/061490/EEB
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directors, at the regular meetings of the board, or whenever they
may require it, an account of all his transactions as treasurer
and of the financial condition of the corporation.

He may sign

certificates of stock.
36.

He shall give the corporation a bond if required

by the board of directors in a sum, and with one or more sureties
satisfactory to the board, for the faithful performance of the
duties of his office, and for the restoration to the corporation,
in case of his death, resignation, retirement or removal from
office, of all books, papers, vouchers, money and other property
of whatever kind in his possession or under his control belonging
to the corporation.

VACANCIES
37.

If the office of any director, or of the chief

executive officer, the president, vice president, secretary or
other officer or agent, one or more, becomes vacant by reason of
death, resignation, retirement, disqualification, removal from
office, or otherwise, the directors then in office, although less
than a quorum, by a majority vote, may choose a successor or
successors who shall hold office for the unexpired term in
respect of which such vacancy occurred.

DUTIES OF OFFICERS MAY BE DELEGATED
38.

In case of the absence of any officer of the

corporation or for any other reason that the board may deem
GBI/061490/EEB
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sufficient, the board may delegate the powers or duties of such
officer to any other officer or to any director, for the time
being, provided a majority of the entire board concur therein.

CERTIFICATES OF STOCK
39.

The certificates of stock of the corporation shall

be numbered and shall be entered in the books of the corporation
as they are issued.

They shall exhibit the holder's name and the

number of shares and shall be signed by the chief executive
officer or president or a vice president and treasurer or
assistant treasurer or secretary or assistant secretary and shall
bear the corporate seal.

TRANSFERS OF STOCK
40.

Upon surrender to the corporation or the transfer

agent of the corporation of a certificate for shares duly
endorsed or accompanied by proper evidence of succession,
assignment or authority to transfer, it ohall be the duty of the
corporation to issue a new certificate to the person entitled
thereto, cancel the old certificate and record the transaction
upon its books.
41.

The corporation shall be entitled to treat the

holder of record of any share or shares of stock as the holder in
fact thereof, and accordingly shall not I>e bound to recognize any
equitable or other claim to or interest in such share on the part
of any other person, whether or not it s.'iall have express or
GBI/061490/EEB
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other notice thereof, save as expressly provided by the laws of
Delaware.

CLOSING OF TRANSFER BOOKS OR FIXING DATE FOR DETERMINATION
OF STOCKHOLDERS OF RECORD FOR CERTAIN PURPOSES
42.

The board of directors shall have the power to

close the stock transfer books of the corporation for a period
not exceeding fifty (50) days preceding the date of any meeting
of stockholders or the date for payment of any dividend or the
date for the allotment of rights or the date when any change or
conversion or exchange of capital stock shall go into effect;
PROVIDED, however, that in lieu of closing the stock transfer
books as aforesaid, the board of directors may fix in advance a
date, not exceeding fifty(50) days preceding the date of any
meeting of stockholders or the date for the payment of any
dividend or the date for the allotment of rights, or the date
when any change, or conversion or exchange of capital stock shall
go into effect, as a record date for the determination of the
stockholders entitled to notice of, and A,o vote at, any such
meeting, or entitled to receive payment r.f any such dividend, or
to any such allotment of rights, or to exercise the rights in
respect of any such change, conversion o*- exchange of capital
stock, and in such case only such stockholders as shall be
stockholders of record on the date so fixed shall be entitled to
such notice of, and to vote at, such meeting, or to receive
payment of such dividend, or to receive such allotment of rights,
GBI/061490/EEB
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or to exercise such rights, as the case may be notwithstanding
any transfer of any stock on the books of the corporation after
any such record date fixed as aforesaid.

LOST CERTIFICATE

43.

Any person claiming a certificate of stock to be

lost, destroyed or stolen shall make an affidavit or affirmation
of that fact and advertise the loss, if *.he board of directors
shall so require, and shall give the corporation a bond of
indemnity, in form and with one or more sureties satisfactory to
the board, for an unspecified amount of an amount set by the
board of directors, whereupon a new certificate may be issued of
the same tenor and for the same number of shares as the one
alleged to be lost, destroyed or stolen, but always subject to
the approval of the board of directors.

INSPECTION OF BOOKS
44.

The directors shall determine from time to time

whether and, if allowed, when and under what conditions and
regulations the accounts and books of the corporation,except such
as may by statute be specifically open to inspection, or any of
them shall be open to the inspection of the stockholders, and the
stockholders rights in this respect are ^nd shall be restricted
and limited accordingly.

GBI/061490/EEB
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CHECKS
45.

All checks or demands for money and notes of the

corporation shall be signed by such officer or officers or agent
as the board of directors may from time to time designate.
46.

The fiscal year shall be determined by the board

of directors.

DIVIDENDS
47.

Dividends upon the capital stock of the

corporation, subject to the provisions of the certificate of
incorporation, if any, may be declared by the board of directors
at any regular or special meeting, pursuant to law.

Dividends

may be paid in cash, in property, or in shares of capital stock.
48.

Before payment of any dividend or making any

distribution of profits, there shall be set aside out of the
surplus or net profits of the corporation such sum or sums as the
directors from time to time, in their absolute discretion, think
proper as a reserve fund to meet contingencies, or for equalizing
dividends or for repair or maintaining any property of the
corporation, or for such other purposes as the directors shall
think conducive to the interest of the corporation.
DIRECTORS' ANNUAL STATEMENT
49.

The board of directors shall present at each

annual meeting, and when called for by t.:e stockholders, at any
special meeting of the stockholders, a full and clear statement
of the business and condition of the corporation.
GBI/061490/EEB
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NOTICES
50.

Except as otherwise specifically provided herein

or required by law, all notices required to be given to any
stockholder, director, officer, employee or agent shall be in
writing and may in every instance be effectively given by hand
delivery to the recipient thereof, by depositing such notice in
the mails, postage paid, or by sending s\.ch notice by prepaid
telegram or mailgram.

Any such notice shall be addressed to such

stockholder, director, officer, employee or agent at his or her
last known address as the same appears on the books of the
corporation.

The time when such notice is received by such

stockholder, director, officer, employee or agent, or by any
person accepting such notice on behalf of such person, if hand
delivered, or dispatched, if delivered through the mails or by
telegram or mailgram, shall be the time of the giving of the
notice.

AMENDMENTS
51.

The board of directors is expressly empowered to

adopt, amend or repeal bylaws of the corporation.

Any adoption,

amendment or repeal of bylaws of the corporation by the board of
directors shall require the approval of a majority of the total
number of authorized directors (whether or not there exist any
vacancies in previously authorized directorships at the time any
resolution providing for adoption, amendment or repeal is
presented to the board).
GBI/061490/EEB
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power to adopt, amend or repeal the bylaws of the corporation in
the manner prescribed by the laws of the State of Delaware.

INDEMNIFICATION OF DIRECTORS AND OFFICERS
52.

Each person who was or is made a party or is

threatened to be made a party to or is involved in any action,
suit or proceeding whether civil, criminal, administrative or
investigative ("proceeding"), by reason of the fact that he or
she or a person of whom he or she is the legal representative, is
or was a director, officer or employee of the corporation or is
or was serving at the request of the corporation as a director,
officer or employee of another corporation, or of a partnership,
joint venture, trust or other enterprise, including service with
respect to employee benefit plans, whether the basis of such
proceeding is alleged action in an official capacity as a
director, officer or employee or in any other capacity while
serving as a director, officer or employee, shall be indemnified
and held harmless by the corporation to the fullest extent
authorized by Delaware Law, as the same exists or may hereafter
be amended (but, in the case of such amendment, only to the
extent that such amendment permits the corporation to provide
broader indemnification rights than said Law permitted to the
corporation to provide prior to the amendment) against all
expenses, liability and loss (including attorneys1 fees,
judgments, fines, ERISA excise taxes or penalties, amounts paid
or to be paid in settlement and amounts expended in seeking
GBI/061490/EEB
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indemnification granted to such person under applicable law, this
bylaw or any agreement with the corporation) reasonably incurred
or suffered by such person in connection therewith and such
indemnification shall continue as to a person who has ceased to
be a director, officer or employee and shall inure to the benefit
of his or her heirs, executors and administrators; provided,
however, that, except as provided in Section 2 of this paragraph,
the corporation shall indemnify any such person seeking indemnity
in connection with an action, suit or proceeding (or part
thereof) initiated by such person only if such action, suit or
proceeding (or part thereof) was authorized by the board of
directors of the corporation.

Such right shall be a contract

right and shall include the right to be paid by the corporation
expenses incurred in defending any such proceeding in advance of
its final disposition; provided, however, that if the Delaware
General Corporation Law then so requires, the payment of such
expenses incurred by a director or officer of the corporation in
his or her capacity as a director or

officer (and not in any

other capacity in which service was or is rendered by such person
while a director of officer, including, without limitation,
service to an employee benefit plan) in advance of the final
disposition of such proceeding, shall be made only upon delivery
to the corporation of an undertaking, by or on behalf of such
director or officer, to repay all amounts so advanced if it
should be determined ultimately that such director or officer is
not entitled to be indemnified under this section or otherwise.
GBI/061490/EEB
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53.

If a claim under paragraph 52 is not paid in full

by the corporation with twenty (20) days after a written claim
has been received by the corporation, the claimant may at any
time thereafter bring suit against the corporation to recover the
unpaid amount of the claim and, if such suit is not frivolous or
brought in bad faith, the claimant shall be entitled to be paid
also the expense of prosecuting such claim.

It shall be a

defense to any such action (other than an action brought to
enforce a claim for expenses incurred in defending any proceeding
in advance of its final disposition where the required
undertaking, if any, has been tendered to this corporation) that
the claimant has not met the standards of conduct which make it
permissible under the Delaware General Corporation Law for the
corporation to indemnify the claimant for the amount claimed, but
the burden of proving such defense shall be on the corporation.
Neither the failure of the corporation (including its board of
directors, independent legal counsel, or its stockholders) to
have made a determination prior to the commencement of such
action that indemnification of the claimant is proper in the
circumstances because he or she has met the applicable standard
of conduct set forth in the Delaware General Corporation Law, nor
an actual determination by the corporation (including its board
of directors, independent legal counsel, or its stockholders)
that the claimant has not met such applicable standard of
conduct, shall be a defense to the action or create a presumption
that claimant has not met the applicable standard of conduct.
GBI/061490/EEB
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54.

The rights conferred on any person in paragraphs

52 and 53 styall not be exclusive of any ether right which such
persons may have or hereafter acquire under any statute,
provision of the certificate of incorporation, bylaw, agreement,
vote of stockholders or disinterested directors or otherwise.
55.

The board of directors is authorized to enter into

a contract with any director, officer, employee or agent of the
corporation, or any person serving at the request of the
corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other
enterprise, including employee benefit p?ans, providing for
indemnification rights equivalent to or, if the board of
directors so determines, greater than, those provided for in
these bylaws.
56.

Any amendment, repeal or modification of any

provision of this section on indemnification by the stockholders
and the directors of the corporation shall not adversely affect
any right or protection of a director or officer of the
corporation existing at the time of such amendment, repeal or
modification.
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MINUTES OF A SPECIAL MEETING
OF THE BOARD OF DIRECTORS OF
GENERAL BIOMETRICS, INC.
NOVEMBER 30, 1989
Pursuant to notice duly given, a Special Meering of the Board of
Directors of General Biometrics, Inc. was held on Thursday,
November 30, 1989 in the offices of Ventana Growth Fund.
All
members of the Board were present except for Robert A. Condie.
Also present were Elaine E. Burroughs, Corporate Secretary; Craig
E.R. Nichols, Corporate Controller; and Dan Dearen of Ventana
Growth Fund.
Mr. Townsen, Chairman of the Board, called the meeting to order at
4:15 p.m.
The first order of business was a report by Mr. Gordy on the status
of the Company's current private offering relating to the sale of
up to $3 million of Limited Partnership interests.
Mr. Gordy
reported that the private placement memorandum had been completed
and that a selling effort by the Placement Agent had begun.
The next order of business was a discussion of the Company's
current financial status with an emphasis being placed on
establishing a "critical mass11 budget and management of cash flow.
Thereafter, a discussion was had concerning the- possibilities of
selling the Company's MRC division. It was the sense of the Board
that Mr. Gordy should investigate the possible sale of this
division and should bring any potential offers to the Board for
further discussion and decision.
Thereupon a discussion was had concerning the vesting requirements
with respect to certain of the Incentive Stock Options previously
granted to key employees, taking into account the fact that certain
of the vesting terms thereunder now appeared to be impractical.
Following discussion, the following resolution was made, seconded,
and unanimously passed:
RESOLVED that the vesting terms with respect
to the Options shown on Exhibit A, a copy of
which shall be attached to and made a part of
these minutes, shall be amended so that henceforth with respect to these Options, 50% thereof
shall vest at such time as the Company shall
have six (6) consecutive months of profitability
and 50% of said Options shall vest at such time
as the Company shall have six (6) consecutive
months of positive cash flow.
A discussion was then had with respect to executive compensation.
The following resolution was thereupon made, seconded, and passed
with Mr. Gordy abstaining from the vote:

RESOLVED, that the Board of Directors hereby
approves an increase in salary for John T. Gordy
to $110,000 per annum effective December 1, 1989.
A discussion was then held concerning the necessity for retaining
key employees during this critical period for the Company. The
following resolution was thereupon made, seconded, and unanimouslypassed:
RESOLVED that the Board of Directors approves
and directs John T. Gordy to offer Incentive
Stock Options from the available ISO pool to
employees who are considered "Key11 to the success
of the Company.
A discussion was then held concerning certain promissory notes
aggregating $1,847,000 executed by the Company in favor of Ventana
Growth Fund and Ventana Growth Fund II. A schedule of said notes
is attached hereto as Exhibit B. Following discussion thereof the
following resolutions were made, seconded and unanimously passed:
RESOLVED, that the execution and delivery of
the promissory notes set forth on Exhibit B
hereto, are hereby ratified, adopted and
approved as and for acts of this Corporation.
RESOLVED, FURTHER, that the Corporation
authorizes, subject to the approval of Ventana
Growth Fund and Ventana Growth Fund II, to
amend each of said notes (1) by amending
Paragraph 3 (1) thereof to extend the date
set forth therein from December 31, 1989 to
March 31, 1991 and (2) by providing
for interest to be payable thereon quarterly.
RESOLVED, FURTHER, that the officers of the
Corporation and each of them are hereby
authorized and directed on behalf of the
Corporation and in its name, to take all
further actions and execute all further
documents necessary or desirable in order
to carry out the purpose and intent of the
aforesaid resolutions.
A discussion was then held concerning capitalizing certain software
development
costs
of
the
Company's
DataGene
Scientific
Laboratories, Inc. subsidiary. Following discussion, the following
resolution was made, seconded and unanimously passed:

WHEREAS, DataGene Scientific Laboratories,
Inc., ("DataGene") the Company's wholly-owned
subsidiary, carries on its balance sheet (and
thereby in the Company's consolidated financial
statements) capitalized software development
costs in amounts totaling $462,923.57 from
prior fiscal years; and
WHEREAS, these costs were capitalized when
DataGene was actively developing the Inheritel
product for sale; and
WHEREAS, DataGene is now and has been for
the last year a dormant Corporation without
the facilities or the funds to proceed with the
development, production and marketing of the
Inheritel product, nor does it anticipate the
ability to do so in the foreseeable future;
NOW, THEREFORE, BE IT RESOLVED, that the
Controller of the Company be instructed to
expense the entire $462,923.57 in software
development costs as at September 30, 1989.
A discussion was then held concerning the increased time and
attention required by the Company from Ventana Growth Fund.
Following discussion, the following resolution was made, seconded
and unanimously passed :
WHEREAS, the Company has recently required
time and attention from Ventana Growth Funds
and in particular, Mr. F. Duwaine Townsen, over
and above that routinely required.
BE IT, THEREFORE, RESOLVED, that the Board of
Directors authorizes and directs John T. Gordy
to enter into a Consulting Agreement with Ventana
Growth Funds on behalf of the Company, whereby the
Company will pay Ventana Growth Funds for consulting services at the rate of $2,000 per month
retroactively from May 1989 until January 1990.
There being no further business for discussion, the meeting was
duly adjourned at 7:00 p.m.
Respectfully submitted,

Elaine E. Burroughs
Corporate Secretary
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GENERAL BIOMETRICS, INC.
BOARD OF DIRECTORS MEETING
NOVEMBER 30, 1989
EXHIBIT A
U OF
tMPLOYEE

SHARES

ADLER, FRED
ANDERSON, MICHAEL
BURROUGHS, ELAINE
DONOVAN, KERRY
FRANEY, CONNIE
GOLEK, AUDREY
ISAKSEN, JOHN

40,000
5,000
7,500
7,500
7,500

PRICE
0.7500
0.5625
0.5625
0.2000
0.1250
0.1250

kESSLER, RALPH
NICHOLS, CRAIG

5,000
10,000
7,500
15,000

SHbALY, DAVID

5,000

0.1250

VAUGHAN, KENUARD

7,500

0.1250

TOTAL:

0.3125
0.1250
0.8/50

117,500

OPTIONS GRANTED WITH FOUR POINT VESTING SCHEDULE

GENERAL BIOMETRICS, INC,
BRIDGE LOANS
EXHIBIT B
NUMBER

DATE OF NOTE

AMOUNT OF NOTE

1

7-15-88

$ 112,000

2 .

7-26-88

27,000

3

8-2-88

50,000

4

10-3-88

135,000

5

10-14-88

50,000

6

10-16-88

165,000

7

11-1-88

170,000

8

11-15-88

116,000

9

11-23-88

172,000

10

12-7-88

100,000

11

12-23-88

75,000

12

1-3-89

25,000

13

1-17-89

100,000

14

2-1-89

125,000

15

2-6-89

150,000

16

2-10-89

125,000

17

3-3-89

150,000

TOTAL

1 ,847 ,000
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PROMISSORY NOTE

$112,000,00

San

Diego,
California
J u l y 1 5 , 1988

!•
OBLIGATION- GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED TWELVE
THOUSAND DOLLARS ($112,000).
2.
1NTEBKQT_JIAT£.
Maker further promise* to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9*00% per annum, payable semi-annually.
3.
TERM.
Tho principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER.
As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued fcr 28,000
shares of Maker's common stock. The Warrant price is $1.00 per
share and the expiration date is July 14, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

/-Jbhri

T. Gordy, President

July 15, 1988

(' \

PROMISSORY NOTE
$27,000,00

San D i e g o , C a l i f o r n i a
J u l y 2 6 , 1988

1.
OBLIGATION. GENERAL BIOMETRICS, I N C , ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of TWENTY-SEVEN THOUSAND
DOLLARS ($27,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER.
As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 6,750
shares of Maker's common stock.
The Warrant price is $1.00 per
share and the expiration date is July 25, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC,

<-~-~"U~bhn

T. Gordy, President

July 26, 1988

PROMISSORY NOTE
$50,000.00

San Diego, California
August 2, 1988

1.
PPLISATIQli. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of FIFTY THOUSAND DOLLARS
($50,000)•
2INTEREST RATff. Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER. As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 12,500
shares of Maker's common stock. The Warrant price is $1.00 per
share and the expiration date .is August 1, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of (General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

JPcJhn T. Gordy, PrdB^dent:
August 2, 1988
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PROMISSORY NOTE
$135,000.00

San Diego, California
October 3, 1988

1.
OBLIGATION, GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED THIRTY-FIVE
THOUSAND DOLLARS ($135,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually,
3.
TEEM*
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing or $3,000,000,whichever comes first.
4#
OTHER. As approved by*the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 67,500
shares of Maker 1 s common stock. The Warrant price is $0,125 per
share and the expiration date is October 2, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

jc^rfTT. Cordy, President v ^
October 3, 1988
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PROMISSORY NOTE
$50,000.00

San Diego, California
October 14, 1938

1.
OBLIGATION.
GENERAL BIOMETRICS, INC., ("Maker") , 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH • FUND
("Holder"^ at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of FIFTY THOUSAND DOLLARS
($50,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER.
As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 25,000
shares of Maker's common stock.
The Warrant price is $0,125 per
share and the expiration date is October 13, 1991.
5.
AUTHORITY.
The undersigned individual signing rhis
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

John T. Gordy, President1
October 13, 1988
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PROMISSORY NOTE
$165,000*00

San Diego, California
October 16, 1988

1.
OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received,
hereby promises to pay to VENTANA GROWTH' FUND
("Holder0), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED SIXTY-FIVE
THOUSAND DOLLARS ($165,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually,
3TERJM.
The principal amount of this Note and all
accrued Interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first•
4.
OTHL'K* As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 82,500
shares of Makor'e common stock. The Warrant price is $0,125 per
share and the expiration date is October 15, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC,

October 16, 1988
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PROMISSORY NOTE
$170,000.00

San Diego, California
November 1, 1988

1*
OBLIGATION, GENERAL BIOMETRICS, I N C , ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED SEVENTY
THOUSAND DOLLARS ($170,000).
2.
INTEREST RATE, Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomas due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever cornea first.
4.
<2323B- As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be Issued for
85,000
shares of Maker's common stock. The Warrant price is $0,125 per
share and the axpiration data is October 31, 1991.
5.
AUTHORITYThe undersigned individual signing this
Note represents and warrants that he is the President of Ganeral
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

John T. Gordy, President.
November 1, 1988
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PROMISSORY NOTE
$116,000.00

San Diego, California
November 15, 1988

1OBLIGATION. GENERAL BIOMETRICS, INC. , ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH F U N D II
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED SIXTEEN
THOUSAND DOLLARS ($116,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rata of 9.00% per annum, payable semi-annually.
3.
XBBH»
The principal amount of this Nota and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first,
4.
QTBERAs approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 58,000
shares of Maker's common stock. The Warrant price is $0*125 per
share and the expiration date is November 14, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

Jo£n T. Gordy, Pr^orident
November 15, 1988
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PROMISSORY NOTE
$172,000.00

sun

Diego, California
November 23, 1988

1.
OBLIGATION, GENERAL BIOMETRICS, INC, , ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value racelved, hereby promises to pay to VENTANA GROWTH FUND II
("Holder11), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED SEVENTH-TWO
THOUSAND DOLLARS ($172,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof Interest on the outstanding principal balance of
this Note at the rate of 9-00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first:.
4.
QT11EK. As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 86,000
shares of Maker's common stock. The Warrant price is $0,125 per
share and the expiration date is November 22, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker..
GENERAL BIOMETRICS, INC.
"X

John T. Gordy, ^r-aetident
vember 23, 1988
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PROMISSORY NOTE
$100,000.00

San Diego, California
December 7, 1988

1.
OBLIGATION. GENERAL BIOMETRICS, I N C , ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND II
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED THOUSAND
DOLLARS ($100,000).
2.
INTEREST RATE,
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest• becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER. As approved by the General Biometrics Board of
Directors, Maker will causa Warrants to be issued for 50,000
shares of Maker's common stock. The Warrant price is $0,125 per
share and the expiration date is December 6, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker,
GENERAL BIOMETRICS, INC.

December 8, 1988
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PROMISSORY NOTE
$125,000.00

San Diego, California
February io, 1989

!•
PPLI<?ftTION. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA G R O W T H F U N D I I
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE H U N D R E D T W E N T Y - F I V E
THOUSAND DOLLARS ($125,000).
2.
INTEREST RATE, Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following rhe closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER.
As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be Issued for 62,500
shares of Maker*s common stock. The Warrant price i3 $0,125 per
share and the expiration date is February 9, 1992.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of Gereral
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC-

February 10, 1989
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PROMISSORY NOTE
$75,000.00

San Diego, California
December 23, 1988

1OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND II
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of SEVENTH-FIVE THOUSAND
DOLLARS ($75,000).
2.
INTEREST RATE.
Maker further promises to pay to the
Holder hereof Interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of
this Note and all
accrued interest: becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
QTHJb'K* As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 37,500
shares of Maker's common stock. The Warrant price is $0,125 per
share and the expiration date is December 22, 1991.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

John T. Gordy, President.
\

ecember 23, 1988
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PROMISSORY NOTE
$25,000*00

San Diego, California
January 3, 1989

1.
OBLIGATION, GENERAL BIOMETRICS, INC, , ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, ror
value received, hereby promises to pay to VENTANA GROWTH F U N D II
("Holder"), at 1660 Hotel Circle North, Suita 730, San Diego,
California 92108, the principal amount of TWENTY-FIVE THOUSAND
DOLLARS ($25,000).
2.
INTEREST RATE,
Maker further promises to pay to the
Holder her.eof interest on the outstanding principal balance, of
this Note at tho rate of 9.00% per annum, payable semi-annually•
3.
XSEM«
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comos first.
4.
OTHEB, As approved by the General Biometrlca Board of
Directors, Maker will cause Warrants to be Issued for 12,500
shares of Maker's common stock* The Warrant price is $0*125 per
share and the expiration data is January 2, 1992.
5.
AUTHORITY.
The undersigned Individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

-~-S5>

John T. Gordy, Pre^-idfest;
January 3, 1989

/

j H N - U ^ ~ - t^J

1 &: ^u

i J : Ui_i I D i u

I tL. i «u: o i ^ j ^ ^ u u

»1^1 P l ^

PROMISSORY NOTE
$100,000.00

San Diego, California
January 17, 1989

1.
PBLI5ATIPN* GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VKNTANA GROWTH FUND II
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED THOUSAND
DOLLARS ($100,000).
2«
INTEREST RATE. Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually*
3.
XEBM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) Dacember 31,
1989, or (2) sixty (60) days following the closing of a major
private or public? General Biometrics financing of $3,000,000,whichever comes first.
4.
<2XHEB«
As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 50,000
shares of Maker's common stock. The Warrant price is $0*125 per
share and the expiration date is January 16, 1992.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

January 18, 1989
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PROMISSORY NOTE
$125,000.00

San Diego, California
February l, 1989

1.
OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND II
("Holder11), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED T W E N T Y - F I V E
THOUSAND DOLLARS ($125,000).
2.
INTEREST RATE.
Maker further promises to pay to* the
Holder hereof interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
TERM.
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 3 1,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER. As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for
62,500
shares of Maker 1 s common stock. The Warrant price is $0,125 per
share and the expiration date is January 31, 1992.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on bahalf of Maker.
GENERAL BIOMETRICS, INC.

<3 hn

T 7 Gordy,

PrffBrittent

February 7, 1989

PROMISSORY NOTE
$150,000.00

San Diego, California
February 6, 1909

1.
OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA GROWTH FUND II
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego,
California 92108, the principal amount of ONE HUNDRED FIFTY
THOUSAND DOLLARS ($150,000).
2.
INTEREST RATE.
Maker further promises to pay to- the
Holder hereor interest on the outstanding principal balance of
this Note at the rate of 9.00% per annum, payable semi-annually.
3.
XEfiH*
The principal amount of this Note and all
accrued interest becomes due and payable on (1) December 21,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4.
OTHER. As approved by the General Biometrics Board of
Directors, Maker will causa Warrants to be Issued for 75,000
chares of Maker's common stock. The Warrant price is $0,125 per
share and the expiration date is February 5, 1992.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

February 7, 1989
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PROMISSORY HOTS
§150,000,00

San Diego, California
March 3, 1989

1.
OPfrJQATIQN. GENERAL BIOMETRICS, INC., ("Maker"), 11199
Sorrento Valley Road, Suite A, San Diego, California 92121, for
value received, hereby promises to pay to VENTANA G R O W T H F U N D I I
("Holder"), at 1660 Hotel circle North, Suit* 730, San Diego,
California 92108, the principal amount of O N E H U N D R E D F I F T Y
THOUSAND DOLLARS ($150,000).
2,
INTEREST RATE*
Maker further promises to pay to the
Holder hereof interest on the outstanding principal balance of
thitt Note at the rate of 9*00% per annum, payable semi-annually.
3.
i£jJH.
The principal amount of this Note and all
accrued interest become* due and payable on (1) December 31,
1989, or (2) sixty (60) days following the closing of a major
private or public General Biometrics financing of $3,000,000,whichever comes first.
4*
OTHER«
As approved by the General Biometrics Board of
Directors, Maker will cause Warrants to be issued for 75,000
shares of Maker's common stock. The Warrant price is $0,125 per
share and the expiration date is March 2, 1992.
5.
AUTHORITY.
The undersigned individual signing this
Note represents and warrants that he is the President of General
Biometrics and has been authorized and empowered by the Board of
Directors to execute and deliver"this Note on behalf of Maker.
GENERAL BIOMETRICS, INC.

PresTdSntT
March 3, 1989
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ADDENDUM TO THE
MINUTES OF A SPECIAL MEETING
OF THE BOARD OF DIRECTORS OF
GENERAL BIOMETRICS, INC,
November 30, 1989
This Addendum is to be attached to and be considered a part of the
Minutes of the meeting of the 3oard of Directors of General
Biometrics, Inc., held on November 30, 19.89. The following items
were discussed and resolved by Directors F. Duwaine Townsen,
Chairman, James R. Yarter and John T. Gordy during said meeting in
the absence of the Corporate Secretary.
RESOLVED, that the annual salary of John T, Gordy,
President and CEO of the Company, be raised to $135,000/year
when the Company has shown a profit and a positive cash flow
for three (3) consecutive months as determined by the
Company's Controller.
RESOLVED, that John T. Gordy be granted Incentive Stock
Options (from the Company's ISO pool) for Fifty Thousand
(50,000) shares. These options are for a three-year period at
the fair market value on November 30, 1989 ($0 • 625/share) and
vest immediately.
RESOLVED, that, in the event of the sale of the Company's
Utah division (MRC) , John T. Gordy will be remunerated for his
efforts on the Company's behalf according to the following
schedule:
MRC is sold for less than $500,000; no remuneration.
MRC is sold for $500,000 or greater; Mr. Gordy
receives five (5%) percent of the net sale amount
up to a maximum of Fifty Thousand ($50,000)
Dollars.
RESOLVED, that Ventana Growth Funds, present holder c _
1,261,250 warrants to purchase the Company's common stock a^
$0 .125/share, agrees to transfer 5_0V000 of these warrants into
the name of John T. Gordy upon his achievement of certain
performance goals to the satisfaction of the Board of
Directors. These goals are to be defined and placed on the
Corporate record by the Board of Directors.
This Addendum is hereby attested to on this <^X^ day of March 1990.
:/ '
--//

- - •

F. Duwaine Townsen, /Chairman

Robert1 X. Condie, ^Director

n

John T. Gordy, Director-

